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                                                                  ABSTRACT 
 
The present study was aimed to design some possible novel benzimidazole derivatives as H
+
/K
+
-
ATPase receptor inhibitor, carry out their molecular docking study and finally to evaluate its 
antiulcer activity by Indomethacin induced and Pylorus ligation induced ulcer model. All the 
designed compounds were docked with the crystal structure of  H
+
/K
+
-ATPase receptor (PDB 
ID:2ZBD) using Glide software version 10.1,Schrodinger,LLC,New York, NY, 2015 and a 
series of benzimidazole derivatives have been synthesized based on dock score and interactions. 
The structures of synthesized compounds were characterized by UV,FTIR,
1
H NMR and mass 
spectral analysis. The synthesized compounds were evaluated for their in vitro antioxidant 
activity and in vitro cell viability assay .Acute toxicity study was carried out for the compound 
P-28(dock score:-8.67) based on OECD 423 Guidelines and the compound was found to be safe 
up to the dose of 1000mg/kg. After 6 days pretreatment with the test compound at the 50mg/kg 
(Low dose) ,100mg/kg (High dose) and the standard drug, pantoprazole was administered at the 
dose of (10mg/kg) ,on the 7
th
 day toxicant was administered  and after 4hrs animals were 
sacrificed , ulcer index , gastric volume, gastric pH, total acidity, free acidity was measured. In 
vivo antioxidant activity of  treated group showed a increased level of SOD,CAT,GPX, GSH, 
Total protein and an decreased level of LPO,MPO . Histopathological studies were carried out to 
further analyze the compound. Based on above results ,it was concluded that the compound P-28 
posses significant in vivo antioxidant and antiulcer activity as that of the standard (pantoprazole) 
and can be used as a lead for the development of newer antiulcer agents. 
   
                            Binding pose and ligand interaction of Compound P-28                       
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INTRODUCTION 
 
The stomach is a J-shaped dilated portion of the alimentary tract situated in the 
epigastric, umbilical and left hypochondriac regions of the abdominal cavity. The 
stomach is continous with the oesophagus at the cardiac sphintcter and with the 
duodenum at the pyloric sphincter. It has two curvatures. The lesser curvature is short, 
lies on the posterior surface of the stomach and is downward continuation of the 
posterior wall of the oesophagus. Just before the pyloric sphincter it cures upwards 
.Where the oesophagus joins the stomach the anterior region angles acutely upwards 
,curves downwards forming the greater curvature and then slightly upwards towards 
the pyloric sphincter. The stomach is divided into three regions: the fundus, the body, 
the antrum. At the distal end of the pyloric antrum is the pyloric sphincter.
1 
 
                                     Figure1 
GASTRIC GLANDS: 
2 
Mucosa consist of 2 layers- superfacial and deep. Between the two layers is the 
lamina propria composed of network of fibrocollagenic tissue with a few 
lymphocytes, plasma cells , macrophages and eosinophils. The mucosa is externally 
bounded by muscularis mucosae. Gastric glands are simple or branched tubular glands 
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that emerge on the deeper part of the gastric foveola, inside the gastric areas and 
outlined by the folds of the mucosa. 
There are three types of glands: cardiac glands, oxyntic glands and pyloric glands. 
The cardiac glands mainly contain mucus producing cells. The oxyntic glands is 
dominated by zymogen cells that produce pepsinogen. Parietal cell  (oxyntic cell) 
within the glands secrete hydrochloric acid and intrinsic factor. The pyloric gland 
mucosa in the antrum synthesizes  and releases the hormone gastrin from G cells. 
                       Table 1: Gastric Glands and secretions 
Source Substance 
secreted 
Stimulus for release Function 
Mucous neck cell Mucus Tonic secretion; increased 
with irritation of mucosa 
Physical barrier 
between lumen 
and epithelium 
Bicarbonate Secreted with mucus Buffers gastric 
acid to prevent 
damage to 
epithelium 
Parietal cells Gastric acid 
(HCl) 
         
Acetylcholine,gastrin, 
histamine 
Activates 
pepsin;kills 
bacteria 
Intrinsic factor Complexes 
with vitamin 
B12 to permit 
absorption 
Enterochromaffin –
like cell 
Histamine Acetylcholine, gastrin Stimulates 
gastric acid 
secretion 
Chief cells Pepsin(ogen) Acetylcholine,acid, 
secretin 
Digests protein 
Gastric lipase Digest fats 
D cells Somatostatin Acids in the stomach Inhibit gastric 
acid secretion 
G cells Gastrin Acetylcholine,peptides,and 
amino acids 
Stimulates 
gastric acid 
secretion 
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GASTRIC JUICE AND ITS FUNCTION: 
2 
Gastric juice, thin, strongly acidic ( pH varying from 1 to 3), almost colorless 
liquid secreted by the glands in the lining of the stomach. About 2 litres of gastric 
juice are secreted daily by specified secretory glands in the mucosa. It consist of : 
 Water, mineral salt :secreted by gastric glands 
 Mucus: secreted by globlet cells in the glands and on the stomach surface 
 Hydrochloric acid, intrinsic factor: secreted by parietal cells in the gastic 
glands 
 Inactive enzymes precursors: pepsinogens secreted by chief cells in the gland 
Functions of gastric juice
2 
-Water: liquefies the food swallowed 
-Hydrochloric acid: 
 acidifies the food and stops the action of salivary amylase 
 kills ingested microbes 
 provides the acid environment  
-Pepsinogens are activated to pepsins by hydrochloric acid and by pepsins already 
present in the stomach. They begin the digestion of proteins, breaking them into 
smaller molecules. pepsins act most effectively at pH 1.5to3.5. 
-Intrinsic factor (a protein) is necessary for the absorption of vitamin b12 from the 
ileum. 
-Mucus prevents mechanical injury to the stomach wall by lubricating the contents. It 
prevents chemical injury by acting as a barrier between the stomach wall and the 
corrosive gastric juice. Hydrochloric acid is present in potentially damaging 
concentrations and pepsins digest protein. 
Gastric lipase: splits the triglycerides in fat molecules into fatty acid and 
monoglycerides. 
 
 
                                                                                                                          
INTRODUCTION 
 
Dept. of Pharmacology.KMCH COP Page 4 
 
REGULATION OF ACID SECRETION:
2
 
The major function of gastric acid are to dissolve food fibres, act as bactericide 
against swallowed organisms, and transform pepsinogen to pepsin. The production of 
acid by the parietal cells requires the transport of hydrogen and chloride from the 
parietal cell to the stomach lumen. Acid is formed in the parietal cells, firstly through 
the hydrolysis of water. At a high rate of acid secretion, bicarbonates moves into the 
plasma, creating an‟ alkaline tide‟ in the venous blood, which also may result in a 
more alkaline urine. 
                    Acid secretion by parietal cells is stimulated by acetylcholine (a 
neurotransmitter), gastrin (a hormone) and histamine (a biochemical mediator) and is 
inhibited by somatostatin (a hormone). The vagus nerve also liberate acetylcholine 
and stimulates the secretion of histamine. Histamine secretion is also stimulated by 
gastrin. Histamine receptors in the gastric mucosa are H2 receptors. Gastric lipase is 
secreated by glands in the fundus of the stomach and is most effective in an acid 
environment. 
Parietal cell acid secretion is initiated by a variety of factors related to food ingestion. 
Regulation is via central, peripheral and cellular mechanisms. 
 Acid is produced by the carbonic anhydrase-mediated catalysis of CO2 and H2O to 
form H
+
 and HCO3 
-
. H
+
 ions are then exchanged for K
+
 by the H
+
/K
+
-ATPase pump 
and later coupled with Cl
-
 ions entering the parietal cell from the blood in exchange 
for HCO3 
-
. 
Most of the vagal fibers supplying the stomach are afferent and transmitt information 
to the brain regarding mechanical and chemical changes in the stomach. The efferent 
fibers are preganglionic neurons that do not directly stimulate the parietal cells, but 
rather synapse with postganglionic neurons in the wall of the stomach. These neurons 
contain neurotransmitters, such as acetylcholine, gastrin-releasing peptide (GRP), 
vasoactive intestinal peptide (VIP), pituitary adenylate cyclase-activating polypeptide 
(PACAP), nitric oxide and substance P. Through these messengers, postganglionic 
neurons are able to maintain acid secretion directly by influencing the parietal cell, or 
indirectly by modulating the secretion of hormonal and paracrine ligands. 
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Sympathetic receptors of the stomach composed of unmyelinated nerve endings 
located within the smooth muscle layer. They recognize chemical stimuli more than 
mechanical stimulation and play a role in carring pain sensation associated with 
inflammatory states, such as gastritis. 
The principal stimulants for acid secretion are histamine, gastrin and acetylcholine 
released from postganglionic enteric neurons. These increase intracellular levels of 
adenosine 3´,5´,-cyclic monophosphate (cAMP), inositol triphosphate (IP3), 
diacylglycerol and calcium. This sequence of events create H
+
/K
+
-ATPase rich 
tubulovesicles to fuse into the apical plasma membrane allowing the H
+
/K
+
-ATPase to 
secrete protons directly into the lumen of the canaliculus of the parietal cell and then 
into the lumen of the gastric gland. 
Histamine: Histamine is produced in ECL cells located in the oxyntic mucosa which 
serves as the major paracrine stimulator of acid secretion. It is produced in ECL cells 
by decarboxylation of L-histidine by histidine  decarboxylase (HDC). In the gut, H2 
receptors on the parietal cell increase adenylate cyclase activity and produce cAMP. 
HDC promoter activity is upregulated by gastrin, H. pylori and PACAP. Targeted 
gene disruption of HDC and the H2 receptor show the key role of gastric acid 
secretion mediated by hormones such as gastrin or PACAP. However, functional 
antagonists of the H2 receptor only partially inhibits acid secretion stimulated by 
cholinergic agents. H2 receptors are also present in smooth muscle and cardiac 
myocyte. H3 agonists stimulate acid secretion indirectly by inhibition of somatostatin-
induced histamine release. There are no approved drugs specifically targeting the H3 
receptor. 
Gastrin : It is the main stimulant of acid secretion during meal stimulation. It is 
produced in response to luminal amino acids derived from dietary intake. At first, 
gastrin is synthesized as a precursor molecule that is split post-translationally into 
acid-stimulatory peptides, of which gastrin-17 and gastrin-34 are the most abundant, 
and N-terminal fragments, of which progastrin 1-35 and progastrin 1-19 
dominate. Gastrin is the most potent endogenous stimulant for gastric acid secretion 
by supporting the synthesis and release of histamine from ECL cells. 
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Gastrin be similar to cholecystokinin (CCK), as it hold an identical C-terminal 
pentapeptide sequence. Two main classes of gastrin/CCK receptors are characterized 
as : CCK-1 and CCK-2. CCK-1 receptors are specific for CCK whereas CCK-2 
receptors identifies  both CCK and gastrin. When CCK-2 receptors become activated 
in parietal and ECL cells, they lead to activation of phospholipase C and release of 
intracellular calcium. It is belived that gastrin will regulate the secretion of histamine 
by increasing the release of stored histamine and by increasing the activity and gene 
transcription of HDC. Gastrin also has a trophic effect on the oxyntic mucosa, 
particularly on ECL cells. A number of neoplasms are gastrin sensitive, including 
gastric carcinoids and cancers of the stomach, colon, pancreas and lung. In the 
stomach, gastrin regulates its effects primarily through the CCK-2 receptor. The 
stimulatory pathways for gastrin release are central and peripheral. Neural pathways 
to the G cells are both inhibitory and stimulatory. Peripheral pathways to the G cells 
are initiated by the presence of food in the stomach as signalled by mechanical 
distention, pH and the presence of amines and specific amino acids. When the pH of 
the gastric lumen falls below 3, a negative feedback mechanism involving calcitonin-
gene related peptide inhibits gastrin release, while hydrogen ions may also protonate 
amino acids and reduce their uptake by the G cells. Luminal pH also stimulates 
sensory nerve cells, amplifying somatostatin release that acts as a paracrine agent to 
suppress gastrin secretion.  
Acetylcholine: Acetylcholine from parasympathetic vagal efferents regulates basal 
acid secretion. It is discharged from postganglionic neurons of the enteric nervous 
system and directly stimulates acid secretion by binding to muscarinic (M3) receptors 
on parietal cells. Acetylcholine may also regulate acid secretion indirectly by 
inhibiting the release of somatostatin through activation of M2 and M4 receptors on D 
cells. The significance of acetylcholine in the PUDs has made it a target of 
anticholinergic drugs. However, the doses usually required to suppress acid secretion 
depends upon undesirable side effects, such as dry mouth, blurred vision and urinary 
retention. 
Somatostatin: Somatostatin is the major physiological inhibitor of acid secretion. It 
is released in two forms. Somatostatin 14 is found mainly in the stomach, pancreas 
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and enteric neurons, while somatostatin 28 is present in the small intestine. 
Somatostatin exercise  tonic inhibitory effects on parietal cells, however, the major 
effects are experienced  by the inhibition of histamine release and gastrin release from 
ECL cells and G cells. The secretion of somatostatin is increased by gastric acid and 
by gastrin. It is repressed by cholinergic activation and increased by vasoactive 
intestinal peptide activation. The somatostatin analog octreotide has a theoretic 
potential in the treatment of acute ulcer bleeding. 
Other Regulators of Acid Secretion: Ghrelin, a stimulant of acid secretion 
involving the vagus nerve and histamine release. Other neurotransmitters, such as the 
neuropeptide GRP have been linked with meal-stimulated acid secretion. GRP 
mediates its effects by gastrin release and it may also be an important 
neurotransmitter in the vagal-cholinergic pathway. CCK may also function as a 
physiologic inhibitor produced by the presence of nutrients in the intestine. Other 
inhibitors of acid secretion that regulate somatostatin release include glucagon-like 
peptide, CCK, VIP, leptin, amylin and EGF. 
 Phases: 
               The secretion of gastric juice is influenced by numerous stimuli that together 
ease  the process of digestion. The main phases of gastric secretion are the Cephalic 
phase, the gastric phase and the intestinal phase. 
Cephalic phase:  
The sensory experiences of smelling ,seeing, tasting, chewing and swallowing food 
contribute to the cephalic phase of secretion .The cephalic phase of acid secretion is 
regulated  by the vagus nerve through the myenteric plexus. Acetylcholine is released 
and stimulates the   chief cells and parietal to secrete acid and pepsinogen 
respectively. The G cells in the antrum liberate gastrin into the blood stream, through 
which it travels to the gastric glands and stimulates the acid secretion. 
Gastric phase:   
The gastric phase of secretion starts with the entry of food in the stomach. The two 
major stimuli have a secretory effect: 
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1) distention of the stomach  
2) the presence of digested protein 
The vagus and enteric nerve plexuses are activated by distention and contribute to 
gastric secretion through a local reflex. Both neural reflexs are controlled by 
acetylcholine and can be blocked by atropine. As digestion continues, products of 
protein break down, which stimulates the release of  gastrin from G cells in the 
antrum. Proteins in the stomach buffer the acid gastric juice and increase the gastric 
pH. Caffeine stimulates acid secretion, as does calcium. 
Intestinal phase:   
The process of movement of chyme from stomach into the duodenum begins the 
intestinal phase of secretion. This phase represents a slow down of the gastric 
secretory response and found to be hormonally mediated by a hormone called entero-
oxyntin. Gastric inhibitory peptide reduces gastric motility and secretion of acid and 
pepsin when chyme enters the duodenum. The intestinal absorption of amino acids 
(protein breakdown products) also stimulates gastric seretion. The intestinal phase of 
gastric secretion is limited by the fact that acid chyme in the duodenum tends to 
inhibit both gastric acid secretion and gastric motility .Acid in the duodenum regulate  
the release of hormone that inhibit acid secretion while stimulating pepsinogen 
secretion. Cholecystokininpancreozymin, suppress gastrin-stimulated acid production. 
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                                   Figure 2: Regulation of acid secretion 
 
Physiology of gastric secretion: 
2 
The hydrogen ion concentration in parietal cell secretions is approximately 3 million 
fold higher than in blood, and chloride is secreted against both a concentration and 
electric gradient. Thus, the ability of the partietal cell to produce  gastric acid is 
depends on active transport. 
The key player in gastric acid secretion is a H
+
/K
+
 ATPase (proton pump) located in 
the cannalicular membrane. This ATPase is magnesium-dependent, and not 
inhibitable by ouabain. The energy for the transport of H
+
 and K is obtained from 
adenosine tri phosphate (ATP). The transport function of H
+
/K
+
- ATPase is managed 
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by intracellular second messengers, either cAMP or calcium ions. The model for 
clarifying acid secretion is as follows: 
 Hydrogen ions are produced within the parietal cells of stomach from 
dissociation of water. The hydroxyl ions formed by this process rapidly 
associate with carbon dioxide to form bicarbonate ion, a reaction mediated 
by carbonic anhydrase. 
H2O+CO2                          Carbonic  anhydrase H+  + HCO3- 
 Bicarbonate ions are transported out of the basolateral membrane in exchange 
for chloride ions. The flow of bicarbonate ions into blood results in a slight 
elevation of blood pH known as the alkaline tide. This process helps in the 
maintainance of intracellular pH in the parietal cell. 
 Potassium and chloride ions are travelled into the lumen of the cannaliculus 
through conductance channels, and which is needed for secretion of acid. 
 Hydrogen ion is transported out of the cell, into the lumen, in exchange for 
potassium through the action of the proton pump;  thus potassium is  
effectively recycled. 
Accumulation of osmotically active H
+
 ion in the cannaliculus creates osmotic 
gradient across the membrane which will effect the outward diffusion of water , the 
resulting gastric juice is 15 mM KCl and 155 mM HCl with a small quantity of NaCl. 
        Acid secretion is regulated by paracrine (histamine), neuronal (acetylcholine) 
and endocrine (gastrin). Their respective receptors (H2, M3 and CCK2 receptors, 
respectively) are located on the basolateral membrane of parietal cells in the fundus 
and body of the stomach. The histamine (H2) receptor is a G-protein coupled receptor 
(GPCR) that stimulates the Gs-adenylcyclase-cyclic AMP-PKA pathway. Gastrin and 
Ach signal through GPCRs that associated with  Gq-PLC-IP3-Ca
2+
 pathway in 
parietal cells. In parietal cells, the Ca
2+
 ion and cyclic AMP  dependent pathways 
stimulates H
+
/K
+
-ATPase (the proton pump),which exchanges potassium and 
hydrogen ions across the parietal cell membrane. 
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                                                     Figure.3 
Peptic ulcer: 3 
    Peptic  ulcer  disease (PUD)  is  characterised  by excavation or inflamed lesions  of  
the  mucosa  and  underlying  tissue  of  the  upper GIT. Peptic ulcers can be acute or 
chronic and deep or superfacial. It is caused by disorder of the normal balance 
between the acidic effect of the gastric juice and protective effect of mucus on the 
gastric epithelial cells. It is viewed as an extension of the gastric erosions viewed in 
acute gastritis. The most common location for ulcers are the stomach and the first 
some centimeters of the duodenum. The  pathophysiology  of  this  GI  disorder  is  
occurs as a result of  as  an imbalance  between  mucosal  defensive  factors  such  as , 
prostaglandin, nitric oxide, peptides, bicarbonate, growth factors and injurious factors 
like smoking, acid, pepsin, , stress, alcohol etc. In healthy individuals, the digestive 
tract is layered with a mucous membrane that protect the layered tissue against the 
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harmful digestive acid; if the amount of acid is  increased or the pH of the acid is 
significantly decreased or the mucus membrane layer becomes too thin or dry ,the 
gastric acid damage the tissue and ulceration occurs. Thus gastric ulcers are similar 
type of peptic ulcer which effects the stomach lining due to an disturbance between  
acid and gastric mucosa. 
Classification: 
11 
A peptic ulcer can be arise at various location: 
 Stomach(called gastric ulcer) 
 Duodenum(called duodenal ulcer) 
 Esophagus(called esophageal ulcer) 
 Meckel‟s diverticulum (called meckel‟s diverticulum ulcer) 
Modified Johnson 
 Type I: Ulcer along the body of the stomach, most often along the lesser curve at 
incisura angularis along the locus minoris resistantiae. Not associated with acid 
hypersecretion. 
 Type II: Ulcer in the body in combination with duodenal ulcers. Associated with 
acid over secretion. 
 Type III: In the pyloric channel within 3 cm of pylorus. Associated with acid over 
secretion. 
 Type IV: Proximal gastroesophageal ulcer 
 Type V: Can occur throughout the stomach. Associated with chronic use of 
NSAIDs (such as ibuprofen). 
Gastric Ulcer 
When a peptic ulcer occurs in stomach, it is called a gastric ulcer. The symptoms of 
gastric ulcers are more specific than symptoms of peptic ulcer. 
Duodenal Ulcer 
When a peptic ulcer occurs in duodenum, it is called a duodenal ulcer. This type of 
peptic ulcer occurs in the first part of the small intestine. Some of the symptoms of a 
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duodenal ulcer are interestingly quite reverse to those of gastric ulcers. Duodenal 
ulcers are the most commonly found in the Western world. 
Lesser Known types of Ulcers 
Esophageal Ulcer 
It mainly occurs in the lower end of the esophagus. Esophageal ulcers are often 
related with a bad case of acid reflux, or GERD as it is commonly called (short for 
Gastro Esophageal Reflux Disease). 
Bleeding Ulcer 
Internal bleeding is caused by a peptic ulcer, is referred as bleeding ulcer - this is the 
most dangerous type of ulcer.  
Refractory Ulcer 
Refractory ulcers are simply peptic ulcers that have not healed after at least 3 months 
of treatment. 
Stress Ulcer 
Stress ulcers are a group of lesions (or lacerations) found in the esophagus, stomach 
or duodenum. These are normally only found in critically ill or severely stressed 
patients. 
Macroscopic appearance
11 
                               
         Figure.4:A benign gastric ulcer (from the antrum) of a gastrectomy specimen. 
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Gastric ulcers are most commonly found on the lesser curvature of the stomach. The 
ulcer is a round to oval parietal defect ("hole"), 2 to 4 cm diameter, with a smooth 
base and perpendicular borders. These borders are not elevated or irregular in the 
acute form of peptic ulcer, regular but with elevated borders and inflammatory 
surrounding in the chronic form. In the ulcerative form of gastric cancer the borders 
are irregular. Surrounding mucosa may present radial folds, as a consequence of the 
parietal scarring. 
Microscopic appearance 
                                      
             Figure.5:Micrograph showing erosive gastric ulcer. (H&E stain) 
A gastric peptic ulcer is a mucosal defect which penetrates the muscularis 
mucosae and lamina propria, produced by acid-pepsin aggression. Ulcer margins are 
perpendicular and present chronic gastritis. During the active phase, the base of the 
ulcer shows 4 zones: inflammatory exudate, fibrinoid necrosis, granulation tissue and 
fibrous tissue. 
Signs and symptoms5 
 bloating and abdominal fullness. 
 Abdominal pain 
 waterbrash  
 loss of appetite and weight loss 
 melena (tarry, foul-smelling feces due to presence of oxidized iron 
from hemoglobin); 
 nausea, and copious vomiting. 
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 hematemesis (vomiting of blood);this is due to bleeding caused by gastric ulcer, 
or from damage to the esophagus from severe/continuing vomiting. 
 Rarely, an ulcer may lead to a gastric or duodenal perforation, which leads 
to acute peritonitis, extreme, stabbing pain, and requires immediate surgery. 
 
Complications5 
Gastrointestinal bleeding is the most common complication. Sudden large bleeding 
can be life-threatening. It occurs when the ulcer erodes one of the blood vessels, such 
as the gastroduodenal artery. 
 Perforation (a hole in the wall of the gastrointestinal tract): If ulcer left untreated 
it often leads to catastrophic consequence. Spillage of stomach or intestinal 
content into the abdominal cavity occurs due to erosion of the gastro-intestinal 
wall by the ulcer.  Acute peritonitis, initially chemical and later bacterial 
peritonitis due to perforforation at the anterior surface of the stomach. The first 
sign is sudden intense abdominal pain. Posterior wall perforation leads to bleeding 
due to involvement of gastroduodenal artery that lies posterior to the 1st part of 
duodenum. 
 Penetration: It is a form of perforation in which the hole leads to and the ulcer 
continues into adjacent organs such as the liver and pancreas. Gastric outlet 
obstruction is the narrowing of pyloric canal by scarring and swelling of gastric 
antrum and duodenum due to peptic ulcers. Patient often presents with severe 
vomiting without bile. 
 Obstruction: Pyloric stenosis occurs as a result of development of fibrous scar at 
or near to the pylorus. In the case of cured duodenal ulcer, it causes duodenal 
stenosis. Due to fibrosis and contraction healed ulcers along the lesser curvatures 
may produce „hour glass‟ deformity. 
 Malignant transformation: Cancer is included in the differential diagnosis 
(elucidated by biopsy), Helicobacter pylori as the etiological factor making it 3 to 
6 times more likely to develop stomach cancer from the ulcer. 
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Pathophysiology: 
 
                                  
         
 
  
 
 
 
 
 
                                                                                
 
 
 
 
 
 
 
 
                                                   
                               Figure 6: Pathophysiology of gastric ulcer formation5 
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FACTORS CAUSING PEPTIC ULCER: 
8 
1. Helicobacter  pylori gastritis:6
 
Helicobacter pylorus is a gram negative, motile, microaerophilic, flagellated and 
spiral shaped bacterium that inhibits various areas of the stomach and duodenum. It 
causes a chronic low level inflammation of the stomach lining and is strongly linked 
to the development of duodenal and gastric ulcers and stomach cancer. Type I strains 
of H.pylori have a pathogenic activity, which  encodes the effector protein cytotoxin-
associated gene A(cag A).After entry into the hostcell, cagA effects cell shape, raise 
cell motility, disturbs cell junctional activity and it causes gastric carcinomas and 
gastric ulcers. As a result of H.pylori increased expression of cytokines such as TNF-
α and IL-1β in gastritis will occur. H.pylori-infected gastric mucosa shows 
infilitration of polymorphonuclear leukocytes, lymphocytes ,monocytes and plasma 
cell in the lamia propria and intraepithelial severe neutrophil infiltration. The immune 
system is unable to clear the infection, despite the appearance of antibodies. Thus, the 
bacterium can cause a chronic active gastritis (type B gastritis). Gastrin stimulates the 
production of gastric acid by parietal cells, in H. pylori colonization responses to 
increased gastrin, the increase in acid can contribute to the erosion of the mucosa and 
therefore ulcer formation. 
2. NSAIDs: 5 
                       
When ingested chronically, aspirin, indomethacin and other NSAIDs 
promote gastric ulcer formation. These drugs may injure the gastric mucosa by 
allowing back-diffusion of hydrogen into the mucosa.  NSAIDs also inhibit the 
synthesis of prostaglandins, which are substances with a cytoprotective effect on the 
mucosa.  Endogenous prostaglandins regulate the mucosal blood flow, epithelial cell 
proliferation, epithelial reconstitution, mucus and bicarbonate secretion.
 
 
3.  Prostaglandins: 
            Prostaglandins are 20-carbon fatty acids, produced from arachidonic acid 
through the enzyme cyclooxygenase. Prostaglandins inhibit the leukocytes 
recruitment thereby it causes the decreased beneficial effects of these substances 
when the gastric mucosa is inflsmed.PGE2 is a potent suppressor in release of PAF, 
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histamine and of TNF-α from peritoneal and intestinal mucosal mast cells. 
Prostaglandins also suppress the generation of reative oxygen metabolites by 
neutrophils 
4. Genetic factors: 
                   The lifetime prevalence of developing an ulcer in first degree relatives of 
ulcer patients is about threefold greater than in general population. This may be 
secondary to clustering of H.pylori within families. People with blood type O have an 
above-normal incidence of duodenal ulcers. Genetic influence appear to have greater 
role in duodenal ulcers are evidenced by their occurrence in families, monozygotic 
twins and association with HLA-B5 antigen. 
5. Stress: 
                 A stress ulcer is an acute form of peptic ulcer that tend to accompany 
severe illness , systemic  trauma or neural  injury. Mental stress may be associated 
with stress ulcer. Usually, multiple sites of ulceration are distributed within the 
stomach and duodenum. Decreased mucosal blood flow is an important contributing 
event in stress ulcer formation. Stress ulcers may be classified as ischemic or cushing 
ulcers. 
 6. Smoking : 
                   Smokers have an increased risk of developing peptic ulcer disease                                               
.In addition, cigarette smoking delays ulcer healing and increases the risk and rapidity 
of relapse after the ulcer heals. Nicotine decreases biliary and pancreatic bicarbonate 
secretion. Smoking also accelerates the emptying of stomach acid into the duodenum. 
Reactive oxygen intermediates (ROI) generation and ROI-mediated gastric mucosal 
cell apoptosis are also considered to be important mechanism for aggravation of ulcer 
by cigarette smoke or nicotine. Smoking or smoke extracts impairs both spontaneous 
and drug-induced healing of ulcer. Smoke extracts also inhibit gastric mucosal cell 
proliferation by reducing ornithine decardoxylase activity, which synthesizes growth 
promoting polyamines. 
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7. Ethanol: 
            Ethanol-induced gastric lesions cause depletion of gastric mucus content, 
damaged  mucosal blood flow and mucosal cell injury. It also decreases the secretion 
of bicarbonate (HCO3
-
) and mucus production, ethanol also produces the necrotic 
lesions in gastric mucosa. After the metabolism ethanol releases superoxide anion and 
hydro peroxy free radicals which causes raised lipid peroxidation. Membrane damage, 
cell death, exfoliation and epithelial erosion occurs due to increased lipid peroxide 
content and oxygen derived free radicals. 
  8. Associated disorders: 
             Peptic ulcer disease is more common in patients with hyperthyroidism, 
emphysema, rheumatoid arthritis, and alcoholic cirrhosis. 
 9. Advanced age: 
             Degenenaration of the pylorus permits bile reflux into the stomach, creating 
an environment that‟s favors ulcer formation. 
10. Psychological factors: 
              Psychological stress, anxiety, fatigue and ulcer-type personality type  are 
viewed as relatively minor influences to peptic ulcer disease. 
11. Sex: 
           Duodenal ulcer is more commonly in man than women, though gastric ulcer is 
seen to be an equal extent in man and women. 
12. Gastritis: 
             Some degree of gastritis is always present in the region of gastric ulcer, 
though it is not clear whether it is the cause or the effect of ulcer. Besides, the 
population distribution pattern of gastric ulcer is similar to that of chronic gastritis. 
13. Mucus secretion: 
            Any condition that decreases the quantity or quality of normal protective 
mucus „barrier‟ predisposes to the development of peptic ulcer. 
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Dietary factors like;        
14. Alcohols: 
             A known mucosal irritant, alcohol causes marked irritation of gastric mucosa 
if ingested in large quantitites at concentration of 20% or greater .The only association 
between ethanol intake and ulcer disease exist in patients with portal cirrhosis. 
15. Coffee: 
             Both regular and decaffeinated coffee contain peptides that stimulate release 
of gastrin, a hormone that triggers the flow of gastric juice. However, a direct link 
between coffee and peptic ulcer disease is not proven. 
16. Dietary salt: 
             The evidence was found between an association of gastric ulcer and dietry 
salts. The occurrence of gastric ulcer may be linked to the amount of dietry salt 
consumption. The salt was shown to induce gastritis of experimental animals. 
17. Effect of free radicals in gastric ulcer: 
                Oxygen free radicals are detrimental to the integrity of biological tissues 
and mediate their injury. The mechanism of damage involves lipid peroxidation, 
which destroys cell membranes with the release of intracellular components, such as 
lysosomal enzymes, leading to further tissue damage. The radicals also promote 
mucosal damage by causing degradation of the epithelial basement membrane 
components, complete alteration of the cell metabolism and DNA damage. The 
generation of the superoxide anion as a mechanism of damage is well established in 
different models of acute and chronic injury. The body has developed several 
endogenous antioxidant systems to deal with the production of reactive oxygen 
species. These systems can be divided into enzymatic and nonenzymatic groups. The 
enzymatic antioxidants include superoxide dismutase (SOD), which catalyzes the 
conversion of 02- to H2 Oa and Efo O, catalase, which then converts Ha Oa to Ha O 
and Oa and glutathione peroxidase, which reduces HaOa to HaO by reduced 
glutathione (GSH). Re-reduction of the oxidized form of glutathione (GSSG) is then 
catalyzed by glutathione reductase. These enzymes also require trace metal co-factors 
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for maximum efficiency, including selenium for glutathione peroxidase, copper, zinc 
or manganese for SOD and iron for catalase. The nonenzymatic antioxidants include 
the lipid soluble vitamins, vitamin E and vitamin A or provitamin A (beta-carotene), 
and the water-soluble vitamin C and GSH. Glutathione, which is synthesised 
intracellularly from cysteine, glycine, and glutamate, is capable of scavenging 
reactive oxygen species either directly or enzymatically via glutathione peroxidase. In 
addition, GSH is crucial to the maintenance of enzymes and other cellular 
components in a reduced state. The majority of GSH is synthesised in the liver. Its 
biologic role is believed to be a defence against dietary xenobiotics and lipid 
peroxidation . Changes in antioxidative molecule levels may be an important factor in 
ulcer generation. 
Epidemology: 
11
 
 The lifetime risk for developing a peptic ulcer is approximately 10%.They resulted in 
301,000 deaths in 2013 down from 327,000 deaths in 1990.In Western countries the 
percentage of people with Helicobacter pylori infections roughly matches age (i.e., 
20% at age 20, 30% at age 30, 80% at age 80 etc.). Prevalence is higher in third world 
countries where it is estimated at about 70% of the population, whereas developed 
countries show a maximum of 40% ratio. Overall, H. pylori infections show a 
worldwide decrease, more so in developed countries. Transmission is by food, 
contaminated groundwater, and through human saliva (such as from kissing or sharing 
food utensils). 
A minority of cases of H. pylori infection will eventually lead to an ulcer and a larger 
proportion of people will get non-specific discomfort, abdominal pain or gastritis. 
Peptic ulcer disease had a tremendous effect on morbidity and mortality until the last 
decades of the 20th century, when epidemiological trends started to point to an 
impressive fall in its incidence. The reason that the rates of peptic ulcer disease 
decreased is thought to be the development of new effective medication and acid 
suppressants and the discovery of the cause of the condition, H. pylori. 
The incidence of duodenal ulcers has dropped significantly during the last 30 years, 
while the incidence of gastric ulcers has shown a small increase, mainly caused by the 
widespread use of NSAIDs. The drop in incidence is considered to be a cohort-
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phenomenon independent of the progress in treatment of the disease. The cohort-
phenomenon is probably explained by improved standards of living which has 
lowered the incidence of H. pylori infections. 
 
Disability-adjusted life year for peptic ulcer disease per 100,000 inhabitants in 
2004.   no data   less than 20   20–40   40–60   60–80   80–100   100–
120   120–140   140–160   160–180   180–200   200–220   more than 220 
 
 
 
Diagnosing Gastric Ulcers
11 
 
The diagnosis of gastric ulceration is initially based on a physical exam;  
 through history, which determines risk factors; and the presence of 
characteristic symptoms, which are dominated by burning stomach pain.  
 The presence of H.pylori, which can be detected by a blood test, stool test, or 
breath test.  
BLOOD TEST: 
              The blood test determines antibody levels, although it is questionable  
whether a positive antibody test without confirming ulceration or 
inflammation via endoscopy is enough to warrant eradication therapy with 
antibiotics. A blood test is not always genuine for accurate peptic ulcer 
diagnosis because it cannot differentiate between past exposure to H. pylori 
and acute infection. Further, a false negative result is possible with a blood test 
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if the patient has recently taken certain drugs, such as antibiotics or proton 
pump inhibitors. 
 
             STOOL TEST: 
              The stool test involves examining the feces to find excessive numbers 
of H. pylori or antigens made against the bacteria. 
BREATH  TEST: 
               The breath test involves test for H. pylori proliferation via 
radioactive carbon dioxide or urea. 
  ESOPHAGOGASTRODUODENOSCOPY (EGD): 
                 It is a form of endoscopy performed on patients in whom a peptic 
ulcer is suspected.. The endoscope allows for visual identification of the 
mucosal membranes of the gastrointestinal tract .By direct visual 
identification, the location and severity of an ulcer can be described. 
BIOPSY:  
                  Histological examination and staining are undertaken and a culture 
is grown in order to confirm H. pylori infection.  
Prevention12 
             Prevention of gastric ulcers often involves ; 
 Reducing NSAID use and use different medications or alternative approaches 
to relieve pain. If NSAIDs want to take long-term, H2 blockers or proton 
pump inhibitors is also be taken to prevent the development of peptic ulcers. 
 Life style: 
 The risks of peptic ulcers can be reduced by eating bland foods, dairy products 
and small portions during meals, but newer suggestions include eating foods 
rich in fiber, especially fruits and vegetables and whole grains which are 
vitamin-rich. They enhance the body‟s ability to heal stomach irritation and 
prevent ulceration. Foods containing flavonoids, such as apples, cranberries, 
onions, garlic and tea may inhibit the growth of H. pylori 
 Avoiding refined foods (white breads, pastas and sugar),eating less red meat 
and more cold-water fish, using healthy oils (olive oil or coconut oil), and 
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reducing trans-fatty acids are all common dietary suggestions for reducing the 
risk of peptic ulcer. 
 Avoiding smoking is also an important approach because compounds in 
cigarettes obstruct with the protective lining of the stomach, making it more 
vulnerable to the development of ulcers. Smoking also increases stomach acid 
production.  
 Reducing alcohol, coffee, and soda pop consumption can also help prevent 
ulcers as excessive use of these acidic beverages irritates and erodes the 
mucous lining of the stomach and intestines, leading to inflammation, 
ulceration and bleeding. 
  Controlling stress and anxiety is also an important part of ulcer prevention. 
 
The Pharmaceutical Treatment of Gastric Ulcers
4 
 
   1) Proton-Pump Inhibitors 
                      Proton-pump inhibitors are a group of drugs that shows noticeable and 
long-lasting decrease of stomach acid production. These drugs are widely sold  in the 
world and are generally the most potent inhibitors of acid secretion, when compared 
to earlier class of inhibitors called H2-receptor antagonists ( H2 blockers). Proton-
pump inhibitors act by irreversibly blocking the hydrogen/potassium adenosine 
triphosphatase enzyme system (commonly called the gastric proton pump) of the 
stomach‟s parietal cells. The proton-pump is the final stage in stomach acid secretion, 
being directly responsible for secreting hydrogen ions into the gastric lumen and 
making it an ideal target for inhibiting acid secretion. Proton-pump inhibitors reduce 
gastric acid secretion by up to 99 %. Proton-pump inhibitors are given in an inactive 
form, which easily crosses cell membranes and enters into parietal cells, where they 
become activated by the acidic environment. The most commonly used proton-pump 
inhibitors include omeprazole , lansoprazole , dexlansoprazole , esomeprazole , 
pantoprazole and rabeprazole . The vast majority of these drugs are known as 
benzimidazole derivatives. 
Adverse effects: 
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 hypochlorhydria (insufficient hydrochloric acid) can lead to a variety 
of side effects such as B-12 deficiency(which mimics symptoms of 
Alzheimer‟s) 
  increased risk of bone fracture 
 increased risk of certain heart arrhythmias and interstitial nephritis, 
low serum magnesium levels (hypomagnesemia), headaches (the 
most commonly reported adverse effect), nausea, diarrhea, 
abdominal pain, flatulence, constipation, fatigue and dizziness. 
 stopping use can cause an increase in stomach acid production above 
that of normal levels that lasts for several weeks.  
 
 
2) H2 Blockers 
 
H2 blockers are also known as histamine blockers or H2-receptor antagonists. It is a 
competitive antagonists of histamine at the parietal cell H2-receptors in the stomach. 
H2 blockers inhibit the secretion of hydrochloric acid by parietal cells by two 
mechanisms: histamine released by enterochromaffin-like cells in the stomach is 
blocked from binding on parietal cell H2-receptors, which stimulate acid secretion; 
and as a consequence, other substances that promote acid secretion (such as gastrin 
and acetylcholine) have a reduced effect on parietal cells when the H2- receptors are 
blocked. H2 blockers are still commonly used for the treatment of dyspepsia,  In the 
U.S., all four FDA-approved members of the H2 blocker group (cimetidine, ranitidine, 
famotidine and nizatidine) are available over-the-counter in relatively low doses, or 
by prescription in larger doses. Cimetidine became the first “blockbuster drug”. 
 
Adverse effects: 
 hypotension, gynecomastia in males, loss of libido, and impotence. (fewer 
adverse drug reactions) 
3) Antibiotics 
Antibiotics are used to kill bacteria such as H. pylori, but due to resistance and 
adaptability, more than one type is often suggested to be taken at the same time. 
Antibiotic regimens are different throughout the world, but in the U.S., antibiotics 
prescribed for treating H. pylori include amoxicillin, clarithromycin, metronidazole, 
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furazolidone and tetracycline. Antibiotics are usually prescribed for only two weeks at 
a time in order to avoid side effects. 
Adverse effects: 
 acquired resistance to antibiotic therapy 
 serious allergic reactions (including anaphylaxis), nausea, upset     stomach, 
diarrhea, sun sensitivity, disruption of the intestinal flora and fauna. 
 Systemic overgrowth of pathogenic bacteria (such as Clostridium difficile) 
and yeast species (such as Candida albicans), and numerous potential 
interactions with other drugs. 
  
4) Bismuth Salicylate 
Medications that protect the lining of the stomach and small intestine from the 
damaging effects of acid are called cytoprotective agents and it  include the 
medications sucralfate  and misoprostol , and over-the-counter agents such as bismuth 
salicylate. Bismuth compounds may also directly kill H. pylori, but it cannot be used 
as a replacement for antibiotics. Bismuth salicylate, like all salicylates (especially 
aspirin), can cause serious bleeding problems when used alone in patients with 
bleeding ulcers. Bismuth quadruple therapy usually involves combining bismuth 
salicylate with a proton-pump inhibitor, tetracycline and metronidazole for 10-14 
days. The main reasons to add bismuth salicylate to a treatment regimen for gastric 
ulcers is if the patient is still infected with H. pylori after a trial of triple therapy, or if 
the patient cannot take amoxicillin (a penicillin-like antibiotic) because of a penicillin 
allergy, or if the patient has been treated before with a macrolide antibiotic, such as 
clarithromycin. 
Adverse effects:  
 darkening of the stools and/or tongue, and a metallic taste in the mouth. 
 
Summary of Common Pharmaceutical Protocols: 
Proton-pump inhibitor / H2-blocker + clarithromycin + metronidazole / amoxicillin 
Proton-pump inhibitor / H2-blocker + metronidazole + tetracycline / bismuth 
salicylate 
Proton-pump inhibitor / H2-blocker + furazolidone + tetracycline / bismuth salicylate 
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Antacids: 
 They neutralize existing stomach acid, which can provide relief of burning stomach 
pain, heartburn, and indigestion, but they are not used in the treatment for gastric 
ulcers. Antacids do not kill H. pylori and also not block the production of stomach 
acid. Commonly used antacids include aluminum hydroxide, magnesium hydroxide 
(Milk of Magnesia), aluminum hydroxide combined with magnesium hydroxide, 
calcium carbonate, and sodium bicarbonate. It is recommended to take antacids at 
least one hour before or two hours after taking other medications because antacids 
may block the medications from being absorbed and effectively utilized. 
Adverse effects: 
 constipation or diarrhea, depending on the main ingredients of the antacids. 
H
+
/
K+
-ATPase:  
The gastric H
+
/K
+
-ATPase is found in the parietal cell of the stomach and a small 
amount in the renal medulla. This enzyme can be seen in cytoplasmic tubular 
membranes in the resting state and also in the microvilli of the expanded secretory 
canaliculus in the stimulated state of the parietal cell. This morphological change is 
supposed to result from fusion of cytoplasmic vesicles with the rudimentary microvilli 
to form the elongated microvilli of the expanded secretory canaliculus. Once the 
enzyme reaches the canaliculus, the enzyme secrets acid by the exchange of 
cytoplasmic hydronium with extracellular K. The function of K efflux channel is to 
supply K to the luminal surface of the pump to allow H for K exchange.9 
                      The H+/K+-ATPase is the proton pump responsible for gastric acid secretion. 
Using ATP hydrolysis as energy source, it catalyzes the electroneutral exchange of 
protons and K
+
 ions across the cell membrane, generating an extracellular proton 
concentration that can be as much as a million times higher than the intracellular 
concentration. The H
+
/K
+
-ATPase consists of two subunits, a catalytic a subunit of 
about 110 kDa and a heavily glycosylated b subunit of about 35 kDa (with the sugar 
chains, the molecular weight of the b subunit is in the range of 60–80 kDa). The 
catalytic a subunit contains domains for ion and ATP binding, whereas the tightly 
bound b subunit is necessary for enzyme maturation and trafficking to the plasma 
membrane. The H
+
/K
+
-ATPase belongs to the large family of Ptype ATPases which 
also includes the Na
+
/K
+
-ATPase and the sarco-endoplasmic reticulum Ca
2+
-Atpase. 
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P-type ATPases are characterized by an ATP hydrolysis –coupled ion transport cycle 
that proceeds through an intermediate, in which an aspartic acid becomes 
phosphorylated (EP) . The transport mechanism of P-type ATPases was originally 
proposed for the Na
+
/K
+
- ATPase . This mechanism appears to be conserved among 
P-type ATPases, although different family members transport different ions and with 
different stoichiometries. During the transport cycle, the Na
+
/K
+
-ATPase, like all the 
other P-type ATPases including H
+
/K
+
-ATPase, undergoes large conformational 
changes that have been characterized by a number of biochemical structure.
10 
                  Inspite of recently available drugs for peptic ulcer, the aim of the study is 
to design around 30 benzimidazole derivatives and docked with H
+
/K
+
-ATPase 
receptor using GLIDE (Grid-based Ligand Docking from Energetics) program 
(Glide, version  10.1 Schrodinger,  LLC  New York, 2015) and best compound are 
selected based on docking score ,invitro and invivo studies . 
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                                    REVIEW OF LITERATURE 
 
• Vikash Kumar et al..,[2014]17: Reported a series of benzimidazole derivatives  
and discussed the structural –activity relationship of the most potent compounds.  
• Neeraj Agarwal et al..,[2013]18: Reported  that QSAR study was made on novel 
series of biaryl imidazole derivatives acting as H/K-ATPase inhibitors .Also 
found that biaryl imidazoles can undergo hydrogen bonding and hydrophobic 
interaction. Docking studies of this compounds are also exhibited, which shows 
better interaction with receptors than  already marketed  drugs. 
                                  
 
• Avinash patil et al..,[2012]19: This investigation is concerned with synthesis of 
new substituted benzimidazole derivatives with the objective of discovering novel 
and potent antiulcer agent and they are characterized by spectral and elemental  
analysis. The synthesized compounds are screened for antiulcer activity and found 
that the benzimidazole derivatives linked with the piperazine moiety shows good 
antiulcer activity. 
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• Kuldeep Kumar et al..,[2012]20: Reported some new 2-substituted 
benzimidazole derivatives were synthesized from microwave irradiation method 
by condensation of 2-nitro aniline with different carboxylic acids (aromatic, 
aliphatic and heterocyclic) and these compounds are identified by FT-IR and 
1HNMR spectroscopic techniques. 
• Tribhuvan Singh et al..,[2012]21: Reported a series of novel pyrimidylthiomethyl 
benzimidazole and pyrimidylsulfinylmethyl benzimidazoles have been 
synthesized and evaluated for their antiulcer activity and concluded that  sulfinyl 
derivative is more effective than thio analog. 
 
• Khan Farhan.R et al..,[2011]22:Reported a series of new substituted 2-
(pyrimidinylsulfinyl)benzimidazoles derivatives synthesized and evaluation 
against antiulcer and antisecretory activity as a inhibition of H/K-ATPase by 
induction of gastric ulceration in male wistar rats. These series of new compounds 
are characterized by IR and elemental analysis and antiulcer activities of the 
compounds were determined by acetylsalicylic acid method-induced gastric ulcer. 
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• Malladi Srinivas Reddy et al..,[2011]23: Reported a series of six novel 
mercaptobenzimidazole derivatives is synthesized and the compounds are 
characterized by their analytical and spectral data. All the compounds are 
screened for their antiulcer and antimicrobial activity. 2-(1H-benzimidazole-2-
sulfinyl)-N-(4-benzyloxy-phenyl)-acetamide, N-(4-benzyloxy-phenyl)-4-(1H-
benzimidazole-2-sulfinyl) butyramide,N-(4-benzyloxy-phenyl)-4-(5-methoxy-1H-
benzimidazole-2-sulfinyl) butyramide showed significant antiulcer activity. 
 
• GeraldDArtman III et al..,[2010]24: Reported that 2-chloro-1,3-
dimethyllimidazolinium chloride has been found to effectively  and rapidly 
generate 2-aminobenzimidazoles from 1,2-diaminoarenes and isothiocyanates in 
moderate to good yields at room temperature in a one-pot operation. 
• O.Sandhya et al..,[2009]25: Reported a series of  nine new [1-benzyl-2-phenyl-
sudstituted]-1H-5,6-substituted-benzo(d)imidazoles substituted benzaldehydes. 
All these compounds were characterized by IR, 
1
H NMR and Mass spectroscopic 
data. Antioxidant activities of these compounds are evaluated by ferrous induced 
lipid peroxidation in rat brain homogenate. And it was found that compound 
having electron releasing group such a as dimethyl amino, methoxy and hydroxyl 
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substituent at position 1 and 2 of benzimidazoles increases the activities when 
compared to the benzimidazole having no substituent on the 
            rings.  
                                                                
 Swastika Ganguly  et al..,[2009]
26
: Reported about the synthesizing of 2-[5-
substituted-1-H-benzo(d)imidazol-2-ylsulfinyl]methyl-3-substitutedquinazoline-
4-(3H)-one derivatives and tested for antiulcer activity against pylorus ligation-
induced, aspirin induced and ethanol induced ulcer in rat model and synthesized 
compounds were characterized by IR,MASS,
1
H NMR and elemental analysis. 
                                                                                      
 
                                                                                                                                                                                                                                                                                                    
 Xuan Guida et al..,[2006]27: Reported a series of novel 1-substituted-2-
aminobenzimidazole derivatives were synthesized and structures of synthesized 
compounds were confirmed by 
1
H-NMR spectra and by elemental analysis. Acute 
toxicity studies of these compounds were done on mice via toxicity 
(logLD50).QSAR analysis of these chemicals was done based on relationship 
between acute toxicity and the octanol/water partition coefficient (logP). Product 
was identified on basis of 
1
H-NMR spectra. 
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                                  R= -CH3,-H,-CH 2CH 2CH 3 
 Junko Tanaka et al..,[2004]28:Reported the effect of a new benzimidazole 
derivative,ME3407 on gastric acid secretion and gastric and duodenal ulcers in 
rats. And also found that it is effective against shay ulcers, water-immersion 
stress-ulcers acetyl salicylic acid and histamine induced erosion.ME3407 only 
active orally and have direct action on ulcers and acid secretion from the gastric 
membrane. 
                                                                                                                                       
  
 
 
 
 
 R.M. Shafik et al..,[2004]29: Reported that inorder to establish new antiulcer 
agents a series of 2-(2-substituted amino) -1H- benzimidazoles,1 ,3-disubstituted-
3,4-dihydropyrimido [1,6-a] benzimidazoles, 3-substituted-3,4 dihydropyrimidol 
[1,6-a] benzimidazol-1(2H)-thiones and 3-substituted-1,2,3,4-tetra hydropyrimido 
[1,6-a] benzimidazoles were synthesized  and they are evaluated for the gastric 
antisecretory activity using invivo  pylorus ligated rat method.Omeprazole was 
used as reference and the result indicates that the test compound exhibit anti   
secretoryactivity. 
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• Dow Kwon et al..,[2001]30: Reported that the inhibitory effects of IY-81149(2-[[-
4-methoxy-3-methyl)-2-pyridinyl]-methyl-sulfinyl]-5-(1H-pyrol-1-yl)-1H-
benzimidazole,a newly developed proton pump inhibitor on gastric acid secretion 
was investigated on invitro and invivo and this compound shows 2-3 times 
stronger inhibitory activity than omeprazole in pylorus-ligated rats. 
• Sung Yun Cho et al..,[2001]31: Reported that a series of benzimidazole 
derivatives containing oxycyclic pyridine  was prepared and evaluated for their 
H
+
/K
+ 
ATPase inhibitory activity and several of the synthesized compound shows 
potent antisecretory pylorus-ligated rats when administered intraduodenally and 
also found that their inhibitory activity is similar to omeprazole. 
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 Young-Kuk Cung et al..,[1998]32:  Reported  about the study to determine the 
effect of a newly synthesized proton pump inhibitor ,2-dimethylamino-4,5-
dihydrothiazolo[4,5:3,4] pyridol[1,2-a] benzimidazole (YJA2O379-2)on gastric 
H
+
/K
+
- ATPase activity ,acid secretion and experimental gastroduodenal lesions 
or ulcers in rat and found that  YJA20379-2 has potent antisecretory and antiulcer 
effects. 
                                                                                             
 
  
 
 Hyae Gyeong Cheon et al..,[1996]33: Reported the invitro effect of various 
benzimidazole derivatives on gastric H
+
/K
+ -
ATP ase  activity .The result showed 
that the effect of substituents on the benzimidazole ring were not significant. 
Replacement of sulfoxide connecting the two ring system to sulfide result in the 
inactive compound, its suggesting the importance of sulfoxide group in the 
inhibition. And also compound with 5 or 6 membered oxacyclic substituents 
attached to the pyridine ring displayed the most effective inhibitory activity. 
Among the series AU-47 shows better  inhibitory activity and is a relevant 
candidate for the development of antiulcer agent. 
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 Shin-ichi Yamada et al..,[1995]34: Reported a series of 2-[(cycloalka[b] 
pyridinyl)sulfinyl]-1H-benzimidazoles was synthesized and tested for 
antisecretory activity against pentagastrin-induced gastric acid secretion in rats. A 
novel benzimidazole derivative containing a cyclohepta[b]pyridine moiety was 
found  to be the most potent  among the series, which include five to eight 
membered cycloalka [b] pyridine ring system.2-[(6,7,8,9-tetrahydro-5H-
cyclohepta[b]pyridin-9-yl) sulfinyl]-1H-benzimidazole analogs with various 
substituents on the aromatic ring shows superior properties to omeprazole. 
                                                                                                               
 
                                                                                                                
 Okabe et al..,[1992]35: Reported  about the novel imidazole derivative wherein R1 
is hydrogen or an alkyl group having 1-6 carbon atoms ,R
2
 is an alkyl group 
having 2-6 carbon atoms substituted with an alkoxy group having 1-4 carbon 
atoms,R
3
,R
4,
R
5
,R
6
 independently is hydrogen, halogen, an alkyl group having 1-6 
carbon atoms or a fluorine substituted alkoxy group having 1-6 carbon atom and 
this imidazole derivative have antiulcer activity. 
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  BernhardKohl etal .,[1992]36:Reported [(pyridylmethyl)sulfinyl]benzimidazoles 
are a class of highly potent antisecretory (H
+
/K
+
)-ATPase inhibitor. The aim of 
the study was to identify compounds with high H
+
/K
+
-ATPase inhibitory activity 
in stimulated gastric gland possessing acidic pH . And also reported that the 
introduction of 3-methoxy group inhibitors possessing high potency similar 
lansoprazole and omeprazole. 
                                                                                                          
  
 Briving et al .,[1992]37: Reported  that benzimidazole derivative  containing 
comounds and ther use as antiulcer agent and the aim of the study to invent novel 
compounds which inhibit exogenously or endogenously stimulate gastric acid 
secretion and thus useful as antiulcer agent.  
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 Minoru Uchida et al..,[1990]38: Reported a series of 4-substituted 8-[(-2-
benzimidazolyl) sulfinylmethyl]-1,2,3,4-tetrahydroquinolines were synthesized 
and examined for ATPase inhibitory and antisecretory activities. Compounds 
tested were potent H
+
/K
+
ATPase inhibitors and showed good antisecretory 
activity. The compounds like 4-(N-allyl-N-methylamino)-1-ethyl-8-[(5-fluro-6-
methoxy-2-benzimidazolyl)sulfinylmethyl]-1-ethyl-1,2,3,4-tetrahydroquinoline 
have potent activity..The structural activity relationship was also studied. 
           
• John C. Sih et al.,[1990]39: Reported  about the synthesis of N-substituted 
benzimidazole(H
+
-K
+
)ATPase or proton –pump inhibitors. And these compounds 
are synthesized to function as prodrug of the parent N-H compound and evaluated 
their ability in inhibiting gastric (H
+
-K
+
)-ATP ase and gastric acid secretion. The 
N-(acyloxy) alkyl-substituted benzimidazoles showed improved chemical stability 
in solid state and in aqueous solution compared to their parent N-H compounds. 
The N-ethoxy -1-ethyl-substituted benzimidazoles shows equal activity as N-H 
compound in shay rat (10mg/kg). 
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• Susumu Okabe et al.,[1988]40: Reported the effect of a newly synthesized 
benzimidazole derivative NCe-1300-B on H
+
/K
+ 
ATPase in the hog gastric 
mucosa and on the basal gastric acid secretion and necrotizing agent-induced 
gastric lesion in rats. It inhibit the gastric secretion on basis of concentraction-
dependent manner. The antisecretory effect in a dose  of 100mg/kg persist for 
upto 72hr.The effects of N-1300-B is almost similar to that of established proton 
pump inhibitor. 
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 Adelstein et al.,[1988]41: Reported about the invention of 2-[(imidazo[1,2-
a]pyridine-3-ylmethyl)sulfinyl]-1H-benzimidazoles that are useful in treatment of 
ulcers. And reported that this invention relates to 2-[(imidazo[1,2-a]pyridine-3-
ylmethyl)sulfinyl]-1H-benzimidazoles that inhibit (H
+
/K
+
)-ATPase obtained from 
gastric mucosa and thus inhibit acid secretion by parietal cells of the stomach.                       
 
 
                                                                                                   
• Enzo CEREDA et al.,[1987]42: Reported a series of sulfinyl benzimidazoles and 
tested for antisecretory activity. In the initial screening two compounds are tested 
for antiulcer activity. The new compounds showed pharmacological properties 
differ from omeprazole, and they proved to be weak antisecretory and specific 
anti-ulcer activity .And some structural requirements for optimum activity were 
elucidated. 
                         
• G.Raynaud et al.,[1976]
43
: Reported a new compound  7110MD 1-(2-benzoyl 
ethyl)2-(cinnamyl piperazinyl 1-methyl)benzimidazole dimaleate belongs to a 
series of benzimidazole derivative which possess gastric anti secretory and 
antiulcer properties. In pylorus ligated rats for 4hrs, it decreases the volume and 
acid concentration of gastric secretion at doses well below LD50. 
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                                  AIM AND OBJECTIVES 
 
Peptic  ulcer  disease (PUD)  is  characterised  by  inflamed  lesions  or excavation  
of  the  mucosa  and  underlying  tissue  of  the  upper gastrointestinal tract. The 
ulcers are the result of damage to the mucus   membrane that normally protects the  
oesophagus, stomach and  duodenum  from  gastric acid  and pepsin. 
Treatment of ulcer disease is prominently focused on reduction of  aggressive  
factors and strengthening  mucosal defense of stomach and duodenum . These are 
all treated by blocking acid secretion through proton pump inhibitors such as 
benzimidazole  derivatives. 
These derivatives potently inhibit gastric proton pump by converting into active 
metabolite, that is, thiophilic cyclic sulphenamides. This transformation takes 
place in the luminal compartment of secreting parietal cell. The benzimidazole 
contains a benzene ring fused to an imidazole ring. Almost all benzimidazole 
derivatives with their two ring systems bear functional substituents and this leads 
to modification of physico-chemical, metabolic and pharmacokinetic properties of 
drugs. 
 Benzimidazole is a versatile nucleus with various biological activities, and 
many antiulcer drugs have the benzimidazole moiety. 
                             Licensed compounds available in the market 
 
 Benzimidazole derivatives plays important role in medicinal field with so many 
Pharmacological activities such as antimicrobial, antiviral, antiulcer, antidiabetic, 
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anticancer, antifungal, antihistaminics. 
 The  enzyme H+/K+ ATP ase,is responsible for gastric acid production was 
selected for the study .The gastric H
+
/K
+
 ATPase is the member of the P2 type 
ATPase family and undergo cycle of phosphorylation and dephosphorylation 
coupled to the outward and inward transport of  hydrogen and potassium  ions 
in the secretory canaliculus of the parietal cells. 
 Over activity of this enzyme causes hyperacidity by producing more of 
hydrochloric acid inside the stomach. This enzyme, therefore was found to be 
a good target for designing compounds to treat hyperacidity. 
 The design of proton pump inhibitors is focused on achieving long lasting and 
rapid inhibition of acid secretion. The PPIs decrease the amount of acid 
secretion by inhibiting the function of the pump and are useful to treat ulcer. 
 
                                        
                               
 After introduction of the first PPI, the apparent drawbacks of irreversible 
proton pump inhibitors, mainly because of their prolonged acid suppression, 
are becoming a cause of concern and also the main side effects of available 
proton pump inhibitors are confusion, delirium, dementia, cardiovascular risk, 
kidney injuries etc. 
 
 The emphasis has been put on the molecular modulation specifically 
modifying different substituents and its positions in the aromatic system to 
overcome these  drawbacks. 
 
 Hence the aim and objective of study was to design the molecules with 
docking software and synthesis, characterize, novel benzimidazole derivatives  
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as antiulcer agents by H
+
/K
+
ATP ase  inhibition  and   to evaluate its invivo 
and invitro anti ulcer activity. 
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                                            PLAN OF STUDY 
Phase I 
Designing of compounds: Compounds were designed for  the   H+/K
+
ATP ase-receptor 
antagonist. 
Phase II  
Docking analysis: Docking studies of designed compounds were carried out using 
GLIDE (Grid-based Ligand Docking with Energetics) module version 4.5, Schrodinger, 
LLC, New York , NY, 2015. The designed compounds were used for docking on H
+
/K
+
-
ATPase receptor antagonist (PDBID:2ZBD) 
 
Phase III 
Synthesis 
Step I 
 
4-Chloro-2-nitrobenzene 4-Chlorobenzene-1,2-diamine 
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Step II  
 Step III 
4-(5-Chloro-1H-benzo[d]imidazol-2-yl)benzenamine   1-(4-(5-chloro-1H-
benzo[d]imidazol-2-yl)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 
 phenylHydrazine 
Step IV  
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Phase IV  
Characterization: All the newly synthesized compounds were characterized by 
melting point determination, solubility property, TLC analysis and their structures were 
elucidated by IR spectroscopy, H
1
NMR spectroscopy and mass spectroscopy. 
Phase V 
Biological   Evaluation: 
 Invitro antioxidant activity: All the synthesized compounds were 
evaluated for in vitro antioxidant activity by DPPH and ABTS methods. 
 Invitro cell viability assay: Evaluation of cell viability assay was 
conducted in AGS (human epithelial gastric cell) cell lines. 
 Acute toxicity study: Toxicity study of the selected compound (P-28) was 
conducted on female adult Wistar rats (150-200g) following the OECD 423 
guidelines. 
 Antiulcer study: Evaluation of antiulcer activity of P-28 was done by 
Pyloric Ligation induced and Indomethacin induced ulcer model. 
 Invivo antioxidant activity: Estimation of catalase, superoxide dismutase, 
glutathione peroxidase, reduced glutathione, Protein estimation by Lowry’s 
method, Myeloperoxidation was carried out on stomach tissue. 
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                                             METHODOLOGY 
 
METHODOLOGY   PROTOCOL: 
The experimental work was conducted under the following sub headings: 
METHODOLOGY PART I: 
 A library  of novel molecules were designed for the  H+/K+ ATPase receptor. 
 Docking studies of the designed molecules were carried out using glide software version 
10.1 ,Schrodinger, LLC, New York,NY,2015 
 Synthesis of targeted compounds as H+/K+ ATPase antagonist 
 Physicochemical studies and characterization of synthesized compounds 
 Spectral studies characterization of synthesized compounds 
METHODOLOGY PART II: 
 Biological evaluation: 
 Evaluation of in vitro cell viability assay in AGS (human epithelial gastric cell)cell lines 
 Evaluation of invitro antioxidant activity 
 Evaluation of acute toxicity study  following OECD 423 Guidelines 
 Evaluation of antiulcer study: By 1)Indomethacin induced ulcer 
                                                                 2)Pyloric Ligation induced ulcer 
 Evaluation of invivo antioxidant activity :Estimation of catalase, superoxide dismutase, 
glutathione peroxidase, reduced glutathione, Lipid peroxidation, Myeloperoxidation, protein 
by lowry‟s method will be carried out 
 Statistical analysis. 
 Histopathological study: Histolopathology of stomach was carried out to further analyze the 
effect of the test compound. 
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5.1. DESIGNING OF THE NOVEL MOLECULES OF H
+
/K
+
-ATP ase RECEPTOR 
Novel drug molecules were designed and their docking studies have been carried out on H
+
/K
+ 
ATP ase using 
the Glide software to study on their dock score and interacting residues. The details of the designed molecule 
are given in the table: 2 
                                          STRUCTURES OF DESIGNED COMPOUNDS 
   
               
            Compound Code 
 
              R 
 
                                      R1 
 
            P1 
 
              Cl 
 
            
            P2 
 
              Cl 
 
 
             P3 
 
               Cl 
 
 
             P4 
 
 
               Cl 
 
 
 
P5 
 
 
              Cl 
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P6 
 
 
          Cl 
 
 
 
P7 
 
 
          Cl 
 
 
 
           P8 
 
 
           Cl 
 
 
         
 
           P9 
 
          Cl 
 
 
 
          P10 
 
 
Cl 
 
 
 
           P11 
 
 
Cl 
 
 
 
           P12 
 
 
Cl 
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P13 
 
 
Cl 
 
 
 
P14 
 
 
Cl 
 
 
 
 
            P15 
 
 
 
Cl 
 
 
 
P16 
 
 
Cl 
 
 
 
P17 
 
 
Cl 
 
 
 
 
           P18 
 
 
 
Cl 
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P19 
 
 
 
           Cl 
 
 
 
             
           P20 
 
 
Cl 
 
 
 
           P21 
 
 
             Cl 
 
 
 
           P22 
 
 
Cl 
 
 
 
           P23 
 
 
           Cl 
 
 
 
          P24 
 
Cl 
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5.2. DOCKING   STUDIES  
Docking procedures aims to estimate the experimental binding modes and affinities of small 
molecules within the binding site of particular receptor targets and is presently widely used as a 
standard computational tool in drug design for virtual screening studies and lead compound 
optimisation to find novel biologically active molecules. Glide docking uses the assumption of a 
 
          P25 
 
Cl 
 
 
          P26 
 
           Cl 
 
 
           
          P27 
 
 
Cl 
 
 
         P28 
 
Cl 
 
 
P29 
 
Cl 
 
 
 
           P30 
 
Cl 
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rigid receptor, although scaling of vander waals radii of nonpolar atom, which decrease penalties 
for close contacts, can be used to model a light “give” in the receptor and/or ligand. Docking 
studies of designed compounds were carried out using GLIDE (Grid-based Ligand Docking with 
Energetics) module version 10.1, Schrodinger, LLC, New York, NY, 2015. The software package 
is running on multi-processor Linux PC. GLIDE has previously been validated and applied 
successfully to predict the binding orientation of many ligands. 
5.2. a. DOCKING METHODOLOGY 
The steps involved in the docking are as follows: 
Ligand structure: The chemical structure of each ligand was drawn using build module. 
Ligand preparation:  In order to prepare high quality, all atom 3D structures for large 
numbers of drug-like molecules,  starting with the 3D structures  in SD Maestro  format, Lig 
Prep  was used. Lig Prep produced a single, low energy, 3D structure  with corrected chiralities 
for each successfully processed input structure.   
Preparation  of  protein:  The  typical  structure  file  from  the  PDB  is  not  suitable  for 
immediate use in molecular modeling calculations. A typical PDB structure file consists of heavy 
atoms and may include a co-crystallized ligand, water molecules, metal ions and cofactors. 
Some structures are multimeric, and may need to be reduced to a single unit. Because of the limited 
resolution of X-ray experiments, it can be difficult to distinguish between NH and O, and the 
placement of these groups must be checked. PDB structures may be missing information on 
connectivity, which must be assigned, along with bond orders and formal charges. This was done 
using the Protein Preparation Wizard. 
 Receptor grid generation: Receptor grid generation requires a “prepared” structure: an all 
atom structure with   appropriate bond orders  and  formal  charges.  Glide searches for favourable 
interactions between one or more ligand molecules and a receptor molecule, usually a protein. 
The shape and properties of the receptor are represented on a grid by several different sets of 
field that provide progressively more accurate scoring of the ligand poses. The options in each tab 
of the Receptor Grid Generation panel allow defining the receptor structure by excluding any co-
crystallized ligand that may be present, determine the position and size of the active site as it 
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will be represented by receptor grids, and set up Glide constraints. A grid area was generated 
around the binding site of the receptor. 
 Ligand docking: This is carried out using GLIDE DOCK. Glide searches for favourable 
interactions  between  one  or  more  ligand  molecule  and  a  receptor  molecule,  usually a 
protein. Each ligand acts a single molecule, while the receptor may include more than one 
molecule, e.g., a protein and a cofactor. Glide was run in rigid or flexible docking modes; the 
latter automatically generated conformations for each input ligand. The combination of position and 
orientation of a ligand relative to the receptor, along with its conformation in flexible docking, is 
referred to as a ligand pose. The ligand poses that the Glide generates pass through a series of 
hierarchical filter that evaluate the ligand‟s interaction with the receptor. The initial filters test the 
spatial fit of the ligand to the defined active site and examines the complimentarily of ligand-
receptor interactions using a grid-based method patterned after the empirical Chem Score 
function. Poses that passed these initial screens enter the final stage of the algorithm, which 
involves evaluation and minimization of a grid approximation to the OPLS-AA non  bonded  
ligand-receptor  interaction  energy.  Final scoring is then carried out on the energy-minimized 
poses. 
Glide Extra-Precision Mode (XP) – The extra-precision (XP) mode of Glide combines a 
powerful sampling protocol with the use of a custom scoring function designed to identify ligand 
poses that would be expected to have unfavourable energies, based on well-known principles of 
physical chemistry. The presumption is that only active compounds will have available poses that 
avoid these penalties and also receive favourable scores for appropriate hydrophobic contact 
between the protein and the ligand, hydrogen-bonding interactions, and so on. The chief purposes of 
the XP method are to weed out false positives and to provide a better correlation between good 
poses   and  good  scores.  Extra-precision mode is a refinement tool designed for use only on 
good ligand poses. Finally, the minimized poses are re-scored using Schrodinger‟s proprietary 
Glide Score scoring function. Glide Score is based on Chem Score, but includes a steric-clash 
term and adds buried polar terms devised by Schrodinger to penalize electrostatic mismatches: 
           Glide Score = 0.065*vdW + 0.130*Coul + Lipo + Hbond + Metal + BuryP + RotB +Site 
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                               Table 3:Components of the Glide Score (G-Score) 
Component Description 
 
                 vdW 
Vander Waals  energy  term is calculated  with  reduced  net 
ionic charges on groups with formal charges, such as metals, 
carboxylates and guanidiniums. 
 
                 Coul 
Coulomb energy term is calculated with reduced net ionic 
charges on groups with formal charges, such as metals, 
carboxylates and guanidiniums. 
               
                 Lipo 
                                          
Lipophilic contact  term  rewards  favourable  hydrophobic 
interactions. 
 
 
               H-bond 
Hydrogen-bonding term is separated into differently 
weighed components that depend on whether the donor 
and acceptor are neutral, one is neutral and the other is 
charged, or both are charged. 
 
 
                 Metal 
Metal-binding term use only for the interactions with 
anionic acceptor atoms is included. If the net metal charge in 
the apoprotein is positive, the preference for anionic ligands 
is included;   if   the   net   charge   is   zero   the   preference   
is suppressed. 
 
   
               BuryP 
                     
                            
             Penalty   for buried polar groups. 
 
   RotB 
 
        Penalty for freezing rotatable bonds. 
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5.2. b. DOCKING   PROCEDURE 
Docking studies of compounds P-01 to P30 were performed using a membrane protein, 
Hydrogen/Pottassium ATP-ase receptor (PDB ID: 2ZBD) obtained from the RCSB Protein Data 
Bank, http://www.rcsb.org which is represented fig: 7 
The computational modeling studies relied upon the GLIDE (Grid-based Ligand Docking 
from Energetics) program (Glide, version 10.1 Schrodinger, LLC New York, 2015) for the 
docking simulations. These simulations were performed using the X-ray crystal structure of the 
(PDB ID: 2ZBD). All the water molecules in the crystal structure were deleted, bond orders were 
assigned, hydrogen‟s  were  added  and  the  protein  was  then  further  refined  for  the  docking  
studies  by processing it using Schrodinger‟s protein preparation wizard. This procedure 
minimizes the protein to 0.30 Å   RMSD using OPLS-2001 force field.  Ligands were   prepared  
using  build  panel  in maestro.  Further  the  ligands  were  prepared  for  docking  using  LigPrep  
tool  and  were  energy minimized  using  MMFF  Force  Field.  Glide Grid generation panel has  
been  used  to  generate receptor grid for docking. Default XP (Extra Precision) docking 
protocol was used to dock the library ligands. Molecular docking were performed for 30 
compounds using the GLIDE program (Version 10.1, Schrodinger, LLC, New York,) to 
understand the interaction of ligands with H/K-ATPase receptor.  
The Maestro user interface was employed to set up and execute the docking protocol and 
also for analysis of the docking results. H/K ATPase receptor (PDB ID: 2ZBD) was selected 
for docking studies and was prepared for docking through protein preparation wizard, energy 
minimization has been carried out using OPLS-2001 force field. Structures of benzimidazole 
derivatives were sketched using built panel  and  prepared  for  docking  through  LigPrep  module 
(energy minimised using MMFF force field). GLIDE grid generation wizard has been used to 
 
                Site                                           
Polar interactions in the active site. Polar but non-
hydrogen- bonding atoms in a hydrophobic region are 
rewarded. 
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define the docking space. Docking was performed using XP (Extra Precision mode) docking 
protocol. The series of compound that are designed for molecular docking study are present in the 
table: 2 
 
           Fig:  7 MOLECULAR DESCRIPTION OF HYDROGEN/POTTASSIUM ATP-ase RECEPTOR 
                                                                               (PDB ID-2ZBD) 
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5.3. SCHEME OF SYNTHESIS 
STEP 1: 
  
                   4-Chloro-2-nitrobenzene                                          4-Chlorobenzene-1,2-diamine 
 
 
 
 
 
 
                      Structure weight 
 
                                 
                                 111868.54 
 
Polymer 
 
 
1 
 
Type 
 
 
Protein 
 
Length 
 
 
995 
 
Chain 
 
 
A 
 
Organism 
 
                              Homo sapiens 
 
Resolution 
 
 
2.40Å 
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STEP 2: 
 
                          
STEP 3: 
 
4-(5-chloro-1H-benzo[d]imidazol-2-yl)benzenamine             1-(4-(5-chloro-1H-benzo[d]imidazol-2-yl)phenyl 
 Hydrazine 
STEP 4: 
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5.3.1 STEP I: SYNTHESIS OF 4-CHLOROBENZENE-1,2-DIAMINE FROM 4-CHLORO-2-NITRO 
BENZENE 
 
4-Chloro-2-nitro benzene 4-Chlorobenzene-1,2-diamine    
 
PROCEDURE: 
 10g of 4-chloro-2-nitrobenzene , 4.8ml of 20% solution of sodium hydroxide  ,24ml of 95% 
ethanol are placed in round bottom flask connected to reflux condenser. The mixture is stirred 
vigorously and heated on a steam bath until the solution boils gently. The steam is turned off and 
16g zinc dust in portion are added frequently enough to keep the solution boiling. After addition of 
zinc dust, reflux for 1hr until colour changes from deep red to nearly colourless. The hot mixture is 
filtered by suction and zinc residue is returned to flask and extracted  with two 50ml portion of hot 
ethanol. To the combined filterates, added 2-3g of sodium hydro sulfite and the solution is 
concentrated under reduced pressure on steam bath .Then cool in ice bath and yellow crystals are 
collected, washed with ice water. 
 
5.3.2. STEP II:SYNTHESIS OF 4-(5-CHLORO-1H-BENZO[d]IMIDAZOL-2-YL)BENZENAMINE 
FROM 4-CHLOROBENZENE-1,2-DIAMINE 
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 PROCEDURE: 
          4g of 4-(5-Chloro-1H-benzo[d]imidazol-2-yl) benzenamine was condensed with paraamino benzoic 
acid in 50ml of 4N HCl and stirr for 4hr with magnetic stirrer at 80
0
c
.
The product was precipitated by adding 
sodium hydroxide. Filtered and washed with cold water, recrystallized from water and ethanol. 
5.3.3 STEPIII: SYNTHESIS OF 1-(4-(5-CHLORO-1H-BENZO[d] IMIDAZOL-2-YL)PHENYL)HYDRAZINE 
FROM 4-(5-CHLORO-1H-BENZO[D]IMIDAZOL-2-YL)BENZENAMINE 
 
 
 
 
4-(5-chloro-1H-benzo[d]imidazol-2-yl)benzenamine                   1-(4-(5-Chloro-1H-benzo[d]imidazol 
                                                                                                                        -2-yl) phenyl) hydrazine    
PROCEDURE : 
           To a solution of 0.1 mol of 1-(4-(5-Chloro-1H-benzo[d]imidazol-2-yl) phenyl) hydrazine in 100ml of  
water and equimolar amount of Hydrazine hydrate .The reaction mixture was made alkaline by adding  2g 
sodium hydroxide  pellets and few ml of ethanol  was added to give a clear solution .Then  it was heated 
under reflux for 2hr in a round bottom flask  and cooled in ice. The crystallized product was filtered under 
suction and recrystallized from ethanol. 
 
 
 
 
 
 
 
                                                                               METHODOLOGY 
 
Dept. of Pharmacology. KMCH COP Page 59 
 
5.3.4 STEP IV: SYNTHESIS OF BENZIMIDAZOLE DERIVATIVES FROM 1-(4-(5-Chloro-1H-
BENZO[d]IMIDAZOL-2-YL)PHENYL)HYDRAZINE 
 
      
PROCEDURE: 
 To a solution of 1-(4-(5-Chloro-1H-benzo[d]imidazol-2-yl) phenyl) hydrazine (0.1 mol) in 
20ml of ethanol and added slowly to an ethanolic solution of 0.1 mole of carbonyl compound (Aromatic 
aldehyde and ketone) in ethanol was added. Then the reaction mixture was acidified with 4ml of glacial acetic 
acid. Then reflux for half an hour .Cool, filter the precipitate and recrystallized from ethanol. 
5.4. PHYSICOCHEMICAL STUDIES AND CHARACTERIZATION OF SYNTHESIZED                                 
COMPOUNDS 
 5.4. a. Melting point 
Melting points of the synthesized compounds were determined in a one end fused capillary tube 
method by using THERMONIC MODEL-C-LMP-1, Campbell, melting point apparatus and were 
uncorrected. 
 5.4. b. Solubility 
Solubility of synthesized compounds was checked in the following solvent: 
Ethanol 
Methanol 
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Hexane 
Chloroform 
Water 
Dimethyl sulphoxide(DMSO) 
Dimethyl formamide(DMF) 
5.4.c. Thin layer chromatography 
Determination of Rf value is an important technique to identify the formation of synthesized 
compounds and to determine the purity of the compound. Rf value is the characteristic property 
for a compound.  Thin  layer  chromatographic  analysis  was  carried  out  for  all  the  
synthesized compounds  by using silica gel G (0.5 mm thickness) coated over glass plate (12 
x 20 cm) as stationary phase and CHLOROFORM:BENZENE(6:4)as mobile phase. The spots 
were visualized by using iodine vapours. 
  
 
                                  
  
5.5. SPECTRAL STUDIES AND CHARACTERIZATION OF SYNTHESIZED 
COMPOUNDS 
5.5. a. Ultra Violet spectral analysis 
The maximum absorbance or λmax of the synthesized compounds were determined in the 
region of 200-400nm in the concentration of 0.01% w/v in ethanol by using Shimadzu UV 
Pharma Spec 1700 UV-Visible spectrophotometer. 
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5.5. b. Infrared spectral analysis 
The structures of the synthesized compounds  were elucidated  by JASCO  FT-IR  4100 infrared 
spectrophotometer in KBr pellets. The IR value was measured in cm
-1
. 
5.5. c. Nuclear Magnetic Resonance spectroscopy 
The structures of the synthesized compounds were elucidated by Bruker AVANCE 500 MHz 
NMR Spectrometer using DMSO (dimethyl sulphoxide) as internal standard at Sophisticated 
Analytical Instrument Facility (SAIF) IIT MADRAS, Chennai. 
5.5. d. Mass spectroscopy 
The structures of the synthesized compounds were elucidated by JEOL GC MATE II GC-MS at 
Sophisticated   Analytical   Instrument   Facility   (SAIF)   IIT   MADRAS,   Chennai.   The   
mass spectroscopy values were measured in m/e ratio. 
5.6. BIOLOGICAL EVALUATION OF THE SYNTHESIZED COMPOUNDS 
 5.6.1. ESTIMATION OF IN VITRO ANTIOXIDANT ACTIVITY 
 5.6.1. a.DPPH Radical scavenging activity 
Principle
44
  
  The DPPH assay method is based on the reduction of DPPH (1,1-diphenyl-2-picrylhydrazyl), 
which is a stable free radical. The free radical DPPH with an odd electron gives a maximum 
absorption at 517 nm (purple colour).  When an antioxidant  reacts with DPPH, it becomes  
paired off in the presence of hydrogen donor (eg: a free radical scavenging antioxidant) and get 
reduced to DPPH, as a  consequence  of  which  the  absorbance  get  decreased.  Radical   react 
with DPPH-H  form  with resulting decolourisation (yellow colour) with respect to the number of 
electrons captured. More the decolourisation more is the reducing ability. 
            DPPH        +         H-A                                             DPPH-H     +   A       
Purple colour            Antioxidant                                  Yellow  colour 
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Reagents 
  Diphenyl-2-picrylhydrazyl (DPPH) 
   Ethanol 
Procedure 
45, 46 
The free radical scavenging activity of the chemical substance was measured in terms of hydrogen 
donating or radical scavenging ability using the stable DPPH radical method. The DPPH solution 
of 5.91 mg (0.3 mM) in 50 ml methanol was prepared and 1 ml of this solution was added to test 
compounds (P-28, P-12, P-24) and standard ascorbic acid solution at different concentrations. After 
30mins, the absorbance was measured at 517 nm. Lower absorbance of the reaction mixture 
indicates higher free radical scavenging activity. The capability to scavenge the DPPH radical 
was calculated using the following equation: 
                                                                                               
  
 where „A control‟ is the absorbance of the control reaction mixture and „A test‟ is the absorbance    
in the presence of test substance. The mean values were obtained from triplicate experiments. 
 ABTS Radical scavenging activity 
Principle 
47 
The spectrophotometric method using synthetic radical of ABTS (2,2-azinobis (3-ethylbenzoline-
6- sulfonic acid) diammonium salt is used to calculate the total antioxidant capacity of a 
substance. The colourless ABTS molecule is converted to a blue-green coloured radical, ABTS
+. 
which has an absorption maxima at wavelengths 645 nm, 734 nm and 815 nm as well as more 
commonly used maximum  at 415 nm.  Oxidation of ABTS   will commence immediately,  but 
the absorbance  is maximal and stable until more than 6 hrs has elapsed. The maximum of 
absorbance is achieved after 12-16 hrs. Addition of antioxidants to the preformed free radical 
cation reduces ABTS to an  extend and on a time scale depending order based on the antioxidant 
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activity, concentration of the antioxidant and duration of the reaction. Decrease in absorbance after 
addition of antioxidants is directly proportional to the number of ABTS
+. 
radicals.  
Reagents 
     4.9 mM potassium persulphate 
     14 mM 2,2-azinobis (3-ethylbenzoline-6-sulphonic acid) (ABTS) 
Procedure
48, 49
 
ABTS radical cation (ABTS
+.
) was produced by reacting 5 ml of 14 mM ABTS solution with 
5 ml of 4.9 mM potassium persulphate solution and the mixture was allowed to stand in dark 
place at room temperature for 12-16 hrs before use. After the time duration, the mixture was 
diluted with water to yield an absorbance of 0.7 ± 0.02 at 734 nm. Different concentrations of 
test compounds (S-16, S-22, S-25, S-26) and standard ascorbic acid were added and then the 
volume was made to 2ml with ABTS radical solution. The blank solution was prepared by 
mixing 950 µ l of ABTS solution and 50µ l  methanol.  After  6  minutes,  the  absorbance  was  
read  at  734  nm  and  the percentage inhibition was calculated. The experiment was 
performed in triplicate. The scavenging activity of ABTS radical was calculated by using the 
following equation: 
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where  „A  control‟  is  the  absorbance  of  the  control  reaction  mixture  and  „A  test‟  is  the  
sample absorbance in the presence of test substance. The mean values were obtained from 
triplicate experiments 
 
5.6.2 DETERMINATION OF INVITRO CELL VIABILITY ASSAY ON CULTURED 
HUMAN  EPITHELIAL GASTRIC CELLS(AGS) 
Cell culture: 
50, 51 
  Human epithelial gastric cells (AGS) were grown in Eagles Minimum Essentials Medium 
(EMEM) containing 10% Fetal Bovine Serum (FBS).Cells were maintained at 37
0
c, 5% CO2, 95% 
air and 100% relative humidity. Cells were subcultured ever third day by trypsinization with 
Trypsin-EDTA solution and medium changed daily. 
Principle: 
This Colorimetric assay is based on the capacity of mitochondria succinate dehydrogenase 
enzymes in living  cells to reduce the yellow water soluble substrate 3-(4,5-dimethyl thiazol-2-yl)-
2,5-diphenyl tetrazolium bromide(MTT) into a insoluble, colored formazan product which is 
measured spectrophotometrically. Since reduction of MTT can only occur in metabolically active 
cells, the level of activity is a measure of the viability of the cells. 
Procedure: 
The monolayer cell culture was trypsinized to make single cell suspensions and viable cells were 
counted using a hemocytometer and the cell count was adjusted to 2x10
4
 cells per ml using 
EMEM containing 10% Fetal Bovine Serum. To each well of 96 well microtiter plates, 0.1ml of 
diluted cell suspension approximately 20,000cells per well was added. After 24 hours, when the 
monolayer formed the supernatant was flicked off and 100µl of different test compounds at serial 
concentration was added to the cells in microtitre plates and kept for incubation at 37
0
c in 5% CO2 
incubator for 48 hours. After 48 hours, the sample solution in wells was flicked off and 15µl of 
MTT dye (5mg/ml) in phosphate buffered saline was added to each well. The plates were gently 
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shaken and incubated for 4 hours at 37
0
c in 5% CO2 incubator. The supernatant was removed, 
100µl of DMSO was added, and the plates were gently shaken to solubilize the formed formazan. 
The absorbance was measured at 570nm using micro plate reader. The medium without samples 
were served as control and triplicates were maintained for all concentrations. The percentage cell 
viability was then calculated by using equation, 
          % Cell viability = Absorbance of treated cells / Absorbance of control x 100 
5.6.3ACUTE TOXICITY STUDY PROTOCOL 
Name of the study Acute Toxicity 
Guideline followed OECD 423- Acute toxic class method 
52 
                Animals Healthy young adult Wistar rats, 
nulliparous, non pregnant 
 
 
Body weight 150-200 g 
Sex Female 
 
Administration of dose and volume 
5,50,300, 2000 mg/kg body weight in single dose in  
1 ml 
 
 
     Number of group and animals 
 
 1 rat each was used to study LD50 value. Rats were 
dosed in sequence and observed for 48 h. Animals 
were observed for 14 days to study the presence or 
absence of any toxicity sign 
Route of administration Oral by using rat oral feeding needle 
Vehicle Carboxy methyl cellulose (0.5 %) 
Room temperature                                      22 ± 3
0
c 
Humidity 40-60 % 
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Light 12 h :12 h (light-dark cycle) 
                          Feed Standard laboratory food pellets with water ad  
Libitium 
Initial once observations First 30 min and periodically for 24 h 
Special  attention First 1-4 h after drug administration 
Long term observation Upto 14 days 
 
Direct observation parameters 
Tremors, convulsion, salivation, diarrhea, lethargy, 
                           sleep and coma 
 
Additional observation parameters 
Skin and fur, eyes and mucous membrane, 
respiratory, circulatory, autonomic and CNS, 
somatomotor activity and behavioral pattern 
 
  
STUDY PROCEDURE 
Acute oral toxicity study was performed as per the Organization for Economic Co-operation and 
Development (OECD) guideline 423 method. Protocols for the study were approved by the 
Institutional Animal Ethical Committee (IAEC) for animal care (Proposal 
Number:KMCRET/M.Pharm/07/2015-16). The animals were fasted overnight prior to dosing. 
Following the period of fasting, rats were weighed and test compound was administered in a 
single dose to a single animal in sequence by gavage using a oral feeding needle. The test 
compound was suspended in 0.5% carboxy methyl cellulose (CMC) and a volume not exceeding 
1ml/100 g body weight was administered.  After the administration of test compound (P-28), 
food was withheld for 2 hrs. Rats were observed during the first 30 mins followed by periodic 
observation during the first 24 hrs, with special attention given during first 4 hrs and daily 
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thereafter for a total duration of 48 hrs. Observations included any change in skin and fur, eyes 
and mucous membranes, respiratory, circulatory, autonomic and central nervous system, 
somatomotor activity and behaviour pattern. Attention was directed to observations of mortality, 
tremors, convulsions, salivation, diarrhoea, lethargy, sleep and coma. If mortality is observed in 2/3 
or 3/3 animals, then the dose administered is assigned as toxic dose (LD50), mortality observed in 
one animal out of three animals, then the same dose was repeated again to confirm the toxic effect. 
If the mortality is not observed in the given dose, then the treatment proceeds with the next dose to 
another group making the observations as mentioned. 
 5.6.4. PHARMACOLOGICAL EVALUATION OF ANTIULCER ACTIVITY 
5.6.4.a 1)INDOMETHACIN INDUCED ULCER MODEL: 
                 Table 4: Experimental design for Indomethacin induced ulcer 
 
Group 
 
NUMBER OF 
ANIMALS 
 
  
                           TREATMENT 
 
Group I 
 
6 
 
 
Normal control rats 
 
Group II 
 
6 
Ulcer control rats receving Indomethacin(toxicant,25mg/kg bw) p.o 
 
Group III 
 
6 
Rats receving Standard drug (Pantoprazole ,10mg/kg bw) p.o 
 
Group IV 
 
6 
Rats receving Low dose of test drug(50mg/kg bw)  + Indomethacin 
(25mg/kg bw) p.o 
 
Group V 
 
6 
 
Rats receving High dose of test drug(100mg/kg bw)  + Indomethacin 
(25mg/kg bw) p.o 
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EXPERIMENTAL PROCEDURE: 
5.6.4. b. ULCER INDUCTION: 
Rats were administered with a single oral dose of Indomethacin (25 mg/kg body weight). They 
were deprived of food but had free access to water 24 h prior to ulcer induction. Various degrees of 
ulceration have manifested 4 h after Indomethacin administration. 
PRINCIPLE: 
53 
Indomenthacin is a synthetic Non-steroidal anti-inflammatory drug (NSAID) with analgesic and 
antipyretic activity. It is a potent inhibitor of postaglandins synthesis that are important mediators 
of the inflammatory response. The anti-inflammatory action of Indomethacin is due to inhibition of 
vasodilator prostaglandin E2 and prostaglandin I2 synthesized from arachidonic acid through 
cyclo-oxygenase pathway by inhibiting cyclo-oxygenase I (COX-I) and cyclo-oxygenase-II (COX-
II). Deficiency of COX-I is of pivotal importance in anti-inflammatory response of NSAIDs. 
5.6.4. c. PROCEDURE: 
54,55
  
         Species             :           wistar Albino rats  
         Weight              :          100-150g  
         Gender              :          Either sex 
30 Animals were taken and divided into 5 groups. Animals were pretreated with test drug  and 
toxicant for 7 days. The animals were fasted for 48hrs prior the experiment, but had free access to 
water. On the 7
th
 day all the animals excluding the control group were orally given Indomethacin 
25mg/kg .Four hours later these animals were sacrificed  and stomach was cut opened through its 
greater curvature .ulcer score and ulcer index were calculated. 
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5.6.4.d.2)PYLORUS LIGATION INDUCED ULCER: 
              Table 5: Experimental design for pylorus ligation induced ulcer 
 
    GROUPS 
NUMBER 
OF 
ANIMALS 
  
                   TREATMENT 
 Group I       6                   Normal control rats 
Group II       6                    Ulcer control rats 
Group III       6 Rats receiving Standard drug(Pantoprazole 10mg/kg bw) p.o 
Group IV       6 Rats receiving Low dose of test drug(50mg/kg bw) p.o  
Group V       6 Rats receiving High dose of test drug(100mg/kg bw) p.o 
 
5.6.4. e. EXPERIMENTAL PROCEDURE: 
PRINCIPLE: 
56 
Pylorus ligation caused ultra structural changes in the gastrin cells of the pyloric gland area and in 
the histamine-storing ECL and A-like cells of the oxyntic gland area. The size of the gastrin cells 
seemed unaffected. In pylorus ligation the number of cytoplasmic granules reduced. It appears 
unlikely that the ultra structural changes of the ECL and A-like cells reflect an increased rate of 
histamine mobilization. The acid response to pylorus ligation reflects neuronal reflex mechanisms 
exclusively. 
PROCEDURE: 
57,58
 
Species               :         wistar Albino rats 
Weight                :        100-150g 
Gender                :         Either sex 
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30 animals were taken and divided into 5 groups. Animals were pretreated with drugs for 7 days. 
The animals were fasted for 48hrs prior the experiment, but had free access to water. After the 
fasting period, the animals were given the test drug samples p.o, 1hr prior the ligation .Thereafter, 
the rats were anaesthetized  with anesthetic ether. Then pyloric ligation was carried out. Four hours 
later these animals were sacrificed and stomach was cut opened through its greater curvature .Its 
contents emptied into graduated test tubes, volume was recorded, pH was measured by pH meter, 
ulcer score and ulcer index were calculated. 
5.6.5. BIOCHEMICAL PARAMETERS: 
The stomach was carefully excised keeping esophagus closed and opened along greater curvature 
and luminal contents were removed. The gastric contents were collected in a test tube and 
centrifuged. The gastric contents were analyzed for pH, total and free acidity. 
 5.6.5.1. MEASUREMENT OF GASTRIC JUICE VOLUME AND pH GASTRIC JUICE: 
  Gastric juice was collected from each animal and centrifuged at 3000 rpm for 10 min. The   
volume of supernatant was measured and expressed as ml/100g body weight. The pH of the 
supernatant was measured using digital Ph meter after diluting of 1ml of gastric juice with 1ml of 
distilled water. 
5.6.5.2. DETERMINATION OF TOTAL ACIDITY: 
An aliquot of 1ml gastric juice was diluted with 1ml of distilled water was taken into a 50ml conical 
flask and added two drops of phenolphthalein indicator into it and titrated with 0.01N NaOH until a 
permanent pink colour was developed. The total acidity is expressed as mEq/L by the following 
formula: 
                     
                             Acidity             =        volume of NaOH ×N×100mEq/L  
                                                                                          0.1  
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5.6.5.3.DETERMINATION OF FREE ACIDITY: 
An aliquot of 1ml of gastric juice was titrated with 0.01N NaOH using Toper‟s reagent as indicator 
until a canary yellow colour was developed. The free acidity is expressed as mEq/L by the following 
formula: 
                       Acidity       =     =        volume of NaOH ×N×100mEq/L  
                       0.1  
5.6.5.4.ULCER INDEX: 
 The stomachs were opened along the greater curvature, rinsed with saline to remove gastric 
contents and blood clots and examined by a 10X magnifier lens to assess the formation of ulcer. The 
numbers of ulcer was counted .Scoring of ulcer are made as follows: 
Normal coloured stomach …………… 0 
Red coloration…………………………0.5 
Spot ulcer………………………………1 
Hemorrhagic streak……………………1.5 
Deep ulcer……………………………...2 
Perforation……………………………...3 
Mean ulcer score for each animal will be expressed as ulcer index. 
              Ulcer  index(UI)      =   UN+US+UPX10
-1
 
   Where, 
            UI=Ulcer Index , UN=Average number of ulcer per animal; US=Average number of severity 
score; UP=Percentage of animals with ulcer. 
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5.6.5.5. PERCENTAGE INHIBITION: 
 Percentage inhibition of ulceration was calculated as below: 
 % inhibition of ulceration = (Ulcer index control-Ulcer index test) x 100 
 Ulcer index control 
 5.6.6.EVALUATION OF IN VIVO ANTIOXIDANT PROPERTY 
5.6.6. a. PREPARATION OF TISSUE HOMOGENATE 
 The stomach was opened and washed with normal saline scoring the  ulcers. The mucosa 
was scraped from the glandular  part of the stomach, suspended in 5.0 ml of cooled 0.15M Kcl-
10Mm potassium phosphate buffer (pH 7.4)containing 0.1% Triton X -100 and centrifuged at 
10000 rpm for 15min at 5
0
c. 
5.6.6. b. Estimation of Catalase (CAT) 
 Principle 
      The normal antioxidant activity of the enzyme catalase is due to the accelerated decomposition   
of hydrogen peroxide to water and oxygen. This method is based on the rate of decomposition of     
hydrogen peroxide by the enzyme catalase which is measured spectrophotometrically at 570 
nm, since hydrogen peroxide has absorbance on this range.
59 
Requirements 
Dichromate acetic acid reagent (5 % potassium dichromate + glacial acetic acid were mixed at 
1:3 ratio (v/v) 
0.01 M phosphate buffer (pH 7.0) 
0.2 M hydrogen peroxide 
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Assay procedure 
To 1 ml of the tissue homogenate, 4 ml of hydrogen peroxide and 5 ml of phosphate buffer 
were added and mixed well. From this, 1 ml of the solution was taken and mixed with dichromate 
acetic acid  reagent  and  allowed  to  incubate  for  30mins  at  room  temperature.  The  
absorbance  was measured at 570 nm. The activity of catalase was expressed as µ mole of H2O2 
consumed/min/mg protein. 
5.6.6.c Estimation of Superoxide Dismutase (SOD) 
Principle 
Pyrogallol  autoxidizes rapidly in aqueous solution, where the reaction will be faster at higher pH, 
and leads to the  formation of several  intermediate  products. Thus the solution first becomes 
yellow-brown with a spectrum showing a shoulder between 400 and 425nm. Molecular oxygen, 
carrying two unpaired electrons with parallel spins, has a preference for univalent reduction because 
spin restrictions arise when reduction with electron pairs is attempted. The recently discovered 
enzyme superoxide dismutase rapidly dismutases univalently reduced oxygen O2.
-
 i.e., the 
superoxide anion radical (2O2.
-
 + 2 H
+
         O2+ H2O2). The enzyme has proven to be a useful probe 
for studying the participation of the radical in reactions involving oxygen such as autoxidations. 
Thus O2
-
. has been shown to be involved in the autoxidation of e.g. sulphite, adrenalin  and 6-
hydroxydopamine. 
Requirements 
 Pyrogallol 
 Tris- HCL (pH 8.2) 
0.1 Mm EDTA 
Assay procedure 
This method might be used for determination of antioxidant activity of a sample, and it was 
described by McCord and Fridovich. The main purpose of this method that was estimated 5% of 
tissue homogenate after adding 75mM, 30mM, and 2mM from Tris-HCL (pH 8.2), EDTA, and 
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pyrogallol respectively. Then, the absorbance was measured at 420nm. The percentage of inhibition 
was calculated depending on that the ability of enzyme to inhibit of oxidation. So, any changes 
might be happened on the absorbance, it will give a clear picture on the ability of enzyme activity to 
prevent oxidation.
60 
5.6.6. d. Estimation of Glutathione Peroxidase (GPx) 
 Principle 
This  assay is based  on  the reduction  of hydrogen  peroxide  (H2O2),  by  glutathione  
peroxidase through  simultaneous  oxidation  of  reduced  glutathione  (GSH)  to  form  oxidized  
glutathione (GSSG). GSSG is again reduced by glutathione reductase (GR) and β-nicotinamide 
adenine dinucleotide phosphate (NADPH) forming NADP
+
which results in the reduced 
absorbance at 340 nm and recycling the GSH. The decrease in absorbance at 340 nm is 
directly proportional to the GPx concentration.
61 
Requirements 
0.32 M phosphate buffer, pH 7.0 
0.8 mM EDTA and 10 mM sodium azide 
3 mM reduced glutathione 
2.5 mM H2O2 and 10 % TCA 
0.3 M disodium hydrogen phosphate
DTNB solution (40 mg of DTNB in 100 ml of 1% sodium citrate) 
Reduced glutathione 
Assay procedure 
To 0.1 ml of the tissue homogenate, 0.2 ml of EDTA, sodium azide and hydrogen peroxide were 
added and mixed. To this, 0.4 ml of phosphate buffer was added and allowed to incubate at room 
temperature. The reaction was arrested by the addition of 0.5 ml of TCA. The reaction mixture 
was centrifuged at 2000 rpm and the supernatant was collected. To 0.5 ml of the supernatant, 4 ml 
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of disodium hydrogen phosphate and 0.5 ml of DTNB were added and the colour developed was 
read immediately at 420 nm.  The activity of glutathione  peroxidase  was  expressed  as  µ moles  
of glutathione oxidized/min/mg. 
5.6.6.e. Estimation of Reduced Glutathione  (GSH)  
Principle 
DTNB is a disulphide compound, which is reduced by sulfhydryl groups in GSH. This 
reduction leads to the formation of yellow colour, which is measured at 412 nm. 
Requirements 
5 % TCA 
0.6 mM 5,5‟-dithiobis-2-nitrobenzoic acid (DTNB) in 0.2 M sodium phosphate 
0.2 M phosphate buffer, pH 8.0 
Assay procedure 
To 1 ml of the homogenate, 1 ml of the TCA solution was added and centrifuged. The 
supernatant was collected and the precipitate formed was removed. To 0.5 ml of supernatant 2 ml 
of DTNB was added and the volume was made up to 3 ml with phosphate buffer. Then the 
absorbance was read at 412 nm. The amount of glutathione was expressed as µ g/mg protein.
62
5.6.6.f. Determination of Lipid Peroxidation 
Principle 
This assay is based on the reaction between thiobarbituric acid with malonyldialdehyde which 
is formed as a result of polyunsaturated fatty acid oxidation. This reaction leads to the formation 
of pink coloured TBA-MDA complex which is measured at  532 nm.
63 
Requirements 
Thiobarbituric acid (0.37%) 
0.25N HCl and TCA (15%) 
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Assay procedure 
To 0.1 ml of the sample, 2 ml of TBA-TCA-HCl   reagent (ratio of 1:1:1) was added, mixed 
and kept in a water bath for 15 min. Afterwards the solution was cooled and supernatant was 
removed and the absorbance was measured at 535 nm against reference blank. The level of 
lipid peroxidase was given as µ moles of MDA formed/min/mg protein. 
5.6.6.g. ESTIMATION OF PROTEINS: 
Reagents 
Alkaline copper reagent 
Solution A: 2% sodium carbonate in 0.1 N NaOH. 
Solution B: 0.5% copper sulphate in 1% sodium potassium tartarate 
Solution C: 50 ml of solution A was mixed with 1 ml of solution B just before use. 
Folin‟s phenol reagent (commercial reagent, 1:2 dilutions) Bovine serum albumin(BSA). 
Principle: 
64 
This method involves two steps; 
Step: 1-protein binds with copper in alkaline medium and reduces it into cu++. 
Step: 2- the cu++ formed catalyses the oxidation reaction of aromatic amino acids by reducing 
phosphomolybdotungstate to heteropolymolybdanum, which leads to the formation of blue colour 
and absorbance was measured at 640 nm.  
Procedure:
 
0.1 ml homogenate was made up to 1 ml with distilled water and to this; 5 ml of alkaline solution was 
added, mixed well and allowed to stand for 10 min. Then a volume of 0.5ml Folin‟s reagent was added, 
mixed well and incubated at room temperature for another 10 min. The blue colour developed was 
measured at 660 nm against blank. Bovine serum albumin (1 mg/ml) served as the standard and form the 
standard graph obtained; the amount of protein in the sample was calculated and expressed as mg/100 
mg tissue. 
5.6.6.h. ESTIMATION OF MYELOPEROXIDASE(MPO) 
Reagents: 
Phosphate buffer(0.01M) 
H2O2  (0.3mM) 
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Principle: 
Myeloperoxidase activity is a measure of leukocyte infiltration. It oxidizes tyrosine to tyrosyl 
radical using hydrogen peroxide as an oxidizing agent. The enzyme involves in the nitration of 
tyrosine residues, which cause variety of inflammatory disorders.
65
 
Procedure:  
Pieces of inflamed tissues were taken. The tissues  was then rinsed with saline, blotted dry, weighed 
and excised. Minced tissue was homogenized in phosphate buffer (pH 7.4), using remi tissue 
homogenizer. The homogenate was centrifuged at 10000 rpm for 20min at 4
0
C. supernatant was 
discarded, myeloperoxidase activity was measured by DTNB method as follows: 
            0.1ml of tissue homogenate was treated with 0.1ml of TNB and 1ml of sodium acetate buffer 
followed by addition of about 0.8ml of NaCl solution and 35μl of hydrogen peroxide.The change in 
absorbance was measured spectrophotometrically at 490nm. One unit of MPO activity is defined as 
the change in absorbance per minute by 1.0 at room temperature, in the final reaction. 
5.6.7. STATISTICAL ANALYSIS 
All  the  Statistical  analysis  was  performed  by  using  Graph  pad  prism  5.0.  All  the  data  
were expressed as mean ± SEM. Groups of data were expressed with one way analysis of 
variance (ANOVA) followed by Tukey test. P value <0.05 was considered as significant. 
5.6.8. HISTOPATHOLOGICAL STUDY 
All group rat stomach were dissected out about 3 to5 mm and fixed with 10% neutral formalin 
solution. Dehydration process was initiated through a graded alcohol series and embedded in 
paraffin. Sections of about 3 µm were cut out and stained with hematoxylin and eosin. 
Histopathological evaluation was carried out under light microscope.  
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                                                                    DISCUSSION 
 
Peptic ulcer disease refers to painful sores or ulcers in the lining of the stomach or first part of 
the small intestine, called the duodenum. It is caused by disturbance of the normal balance 
between the corrosive effect of gastric juice and the protective effect of mucus on the gastric 
epithelial cells. The  pathophysiology  of  this  gastro-intestinal  disorder  is  viewed  as  an 
imbalance  between  mucosal  defensive  factors  such  as bicarbonate, prostaglandin, nitric 
oxide, peptides, growth factors and injurious factors like acid, pepsin, smoking, stress, alcohol 
etc. 
                        In silico Molecular modeling studies will lead to generation of a potent molecule 
in less time with reduction in the usage of chemicals and animals and also  it will save money. It 
is a process of In-silico- chemico-biological approach of drug designing.  The recent growth in 
molecular sciences and the advances in genomics and proteomics have generated several 
potential new drug targets, leading to changes in the paradigms of antiulcer drug discovery 
toward molecularly targeted therapeutics.  
                      The titled compounds were designed and the docking studies of the 30 designed 
compounds were carried out by using Glide software with Hydrogen-Potassium ATP-ase 
receptor (H
+
/K
+
-ATP-ase)(PDB ID:2ZBD). Based on the docking score  and  interaction the 
targeted compounds was synthesized from 4-chloro-2-nitroaniline as  a starting material, which 
is then converted to 4-(5-chloro-1H-benzo[d]imidazol-2-yl)benzenamine and finally to 1-(4-(5-
chloro-1H-benzo[d]imidazol-2-yl)phenyl hydrazine which reacted with glacial acetic acid 
,alcohol and aldehydes  and ketones  to get the targeted benzimidazoles derivatives .The structure of 
synthesized compounds were characterized by physical and spectral analysis. 
Melting point 
                 Melting point  of  the  synthesized compounds were determined in a one end fused 
capillary tube method by using THERMONIC MODEL-C-LMP-1, Campbell melting point 
apparatus and are uncorrected. Melting point of compound P-28 was found to be 140-143
0
c. 
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Solubility 
        Solubility of the synthesized compounds was checked out in the solvent like ethanol, 
methanol, hexane, chloroform, water, dimethylsulphoxide(DMSO),dimethylformamide 
(DMF).The compounds were found to be soluble in ethanol and DMSO. 
Thin layer chromatography 
                   Thin layer chromatographic analysis was carried out for all synthesized compounds 
by using silica gel G(0.5mm thickness) coated over glass plate(12 x 20 cm)as stationary phase, 
chloroform:benzene(6:4) as mobile phase and the spot was visualized by iodine vapours. 
Determination of Rf value is an important technique to identify the formation of synthesized 
compounds and to determine the purity of the compound . Rf value is the characteristic for each 
of the compound.Rf value of compound P-28 was found to be 0.75. 
Infrared spectral analysis 
Nuclear Magnetic Resonance spectroscopy 
                  The structures of the synthesized compounds were elucidated by Bruker AVANCE 
500 MHz NMR spectrometer using DMSO (dimethyl sulphoxide) as internal standard at 
Sophisticated Analytical Instrument Facility(SAIF)IIT MADRAS,Chennai. The NMR spectra’s 
have showed a characteristic proton resonance shift for the entire synthesized compounds. 
Mass spectroscopy 
                   The structures of the synthesized compounds were to be elucidated by JEOL GC 
MATE II GC-MS at Sophisticated Analytical Instrument Facility (SAIF) IIT MADRAS, 
Chennai.The mass spectroscopic values are measured in m/e ratio and the molecular ion peak 
corresponds to the molecular weight of the compound. The Mass Spectral analysis of the 
                   The structures of the synthesized compounds were elucidated by JASCO FT-IR 4100 
infrared spectrophotometer in KBr pellets. The IR value is measured in cm
-1
 .The spectra’s 
showed the relevant functional group frequency for the designed compounds. 3452cm
-1
: Amine 
NH stretching, 2853cm
-1
: Aliphatic CH-Stretching,1629cm
-1
:C=N Stretching,936cm
-1
:Aromatic 
CH Bending, which confirms the chemical structure of the compound synthesized. 
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synthesized compounds P-28 was performed, and the mass spectrum of the compound was in 
agreement with its molecular weight. 
        Based on the IC50 value , the docking scores, spectral and physical analysis  compound P-28  
was selected for further animal studies against Indomethacin and pylorus ligation induced gastric 
ulcer on Wistar rats. 
Pharmacological studies 
                 In vitro antioxidant studies such as ABTS and DPPH were carried out and the 
synthesized compounds exhibited slightly lower free radical scavenging activity than that of the 
standard ascorbic acid. Further ,in vitro cell viability assay of the synthesized compounds were 
carried out in AGS(human epithelial gastric cell) cell lines using cultured MTT assay. Cell line 
facilitate examination of cell types for their physiological and pathological processes without the 
use of animal models. Further,it could be used for studying the effect of various compounds on 
specific cell types. Based on the results of in vitro cell viability assay, concentraction of 
synthesized compounds for studying antiulcer activity was determined. A significant reduction in 
cell damage was observed when the AGS cells were pretreated with compound P-28 compared to 
control. 
        Treatment of ulcer diseases is prominently focused on reduction of aggressive factors and 
strengthening mucosal defense of stomach and duodenum. These are all treated by blocking acid 
secretion through proton pump inhibitors such as benzimidazole derivatives. Almost all 
benzimidazole derivatives with their two ring systems bear different functional substituents and 
this leads to essential modification of the physico-chemical, metabolic and pharmacokinetic 
properties of these drugs. Tissue selectivity of this type of antiulcer drugs is based on both their 
pH dependent accumulation, as weak bases in the acidic compartment of secreting parietal cell, 
and the subsequent acid-induced rearrangement of the parent compound to the 
pharmacologically active principle . The enzyme H
+
/K
+
 ATPase is responsible for gastric acid 
production and is located in the secretary membranes of the parietal cell . Gastric acid secretion 
is regulated by interaction of basolateral parietal cell receptors with their physiological 
stimulants gastrin, acetylcholine, and histamine. The irreversible inhibition of the H
+
 /K
+
 -
ATPase, a means of controlling gastric pH has attracted considerable attention in recent years 
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with the discovery of the benzimidazole class of antisecretory agents. Synthesis and utility of 
novel substituted benzimidazole derivatives is evaluated  by their ability to inhibit gastric H+ /K+-
ATPase and by blocking the gastric acid secretion .91 
Indomethacin induced ulcer  
In the present study ,ulcer control group showed signs of elevated gastric volume, decreased 
gastric PH ,increased total acidity and free acidity and ulcer index followed by oral administration 
of Indomethacin .Ulcer induction in rats by Indomethacin is  related with inhibition of 
cyclooxygenase that prevents prostaglandin biosynthesis.
92
 Compound P-28 was found to be 
produce a significant(P˂0.001) reduction in ulcer index in treated groups . It was also found to 
have significant (P<0.001) increase in the pH and decrease in the acid volume and total acidity of 
gastric fluid in pylorus-ligation model, thus proving its anti-ulcer activity when compared to that 
of ulcer control group. Hence the test compound and standard drug has significant antiulcer 
activity against ulcer control group. 
Pylorus ligation indced ulcer 
                    In the present study, ulcer control group showed signs of elevated gastric volume, 
decreased gastric PH, increased total acidity and free acidity and ulcer index. Ligation of the 
pylorus induces ulcers that serve as a useful model for investigating the efficacy of drugs on 
gastric secretions. These ulcers result from autodigestion of the gastric mucosa leading to a 
breakdown of the gastric mucosal barrier. So, basically an increase in acid-pepsin accumulation 
due to pylorus obstruction may cause subsequent mucosal digestion. The model is useful for 
evaluating the effects of anti-secretory drugs that reduce secretion of gastric aggressive factors 
such as acid and pepsin. The model is also useful for assessing the cytoprotective effects of drugs 
that increase secretion of mucus.
93
 Compound P-28 was found to be produce an significant 
(P<0.001) reduction in ulcer index in treated groups . It was also found to have significant 
(P<0.001) increase in  the  pH and decrease in  the acid volume and total acidity of gastric fluid 
in pylorus-ligation model, thus proving its anti-ulcer activity when compared to that of ulcer 
control group. Hence the test compound and standard drug has significant antiulcer activity 
against ulcer control group. 
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                    Oxidative stress plays an important role in the pathogenesis of various diseases 
including gastric ulcer, with antioxidants being reported to play a significant role in the 
protection of gastric mucosa against various necrotic agents. Reactive oxygen species are 
involved in the pathogenesis of pylorus ligation-induced and Indomethacin induced  gastric 
mucosal injury in vivo. As compared to normal rats, pylorus-ligation and Indomethacin  
administration was found to increase lipid peroxidation and decrease SOD, catalase and reduced 
glutathione, GPX  ,total protein ,increased MPO  in the control groups, thus leading to oxidative 
stress. Preventive antioxidants, such as superoxide dismutase (SOD) and catalase (CAT) 
enzymes are the first line of defence against reactive oxygen species. Reduced glutathione (GSH) 
is a major low molecular weight scavenger of free radicals in the cytoplasm and an important 
inhibitor of free radical mediated lipid peroxidation . Administration of Compound P-28 in both 
the models resulted in a significant increase in the SOD, catalase , reduced glutathione levels, 
GPX ,total protein, reduced MPO as compared to the control animals, which suggests its efficacy 
in preventing free radical induced damage. Lipid peroxidation is a free radical mediated process, 
which has been implicated in a variety of disease states. It involves the formation and 
propagation of lipid radicals, the uptake of oxygen and rearrangement of double bonds in 
unsaturated lipids which eventually results in destruction of membrane lipids. The control groups 
reported an increase in lipid peroxidation. The study has revealed a significant decrease in lipid 
peroxidation by Compound P-28 in both the experimental models, which suggests its protective 
effect. 
93,94 
                                    Thus the compound P-28 confirmed the free radical scavenging potential 
and it has potential to prevent the macro and microvascular complications 
  Histopathological study    
 The control group of rats pylorus ligated model showed histopathological changes of the gastric 
mucosa characterised by loss of glandular architecture, oedema   and infiltration by inflammatory 
cells. Few glands show reactive atypia. Laminapropria shows scattered chronic inflammatory 
infiltrates and neutrophils. Submucosa shows congested vessels and chronic inflammation. The 
rats treated with Compound P-28 (50mg/kg) and pantoprazole (10mg/kg) showed minimum 
ulceration and inflammatory infilterates. However, Compound P-28 (100 mg/kg) and 
pantoprazole(10mg/kg) showed significant intact and normal mucosa . 
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Histopathology of the stomach of the control animals of indomethacin induced ulcer model 
showed few scattered chronic inflammatory infiltrates in lamiapropia region. Submucosa shows 
significant pathological changes. Gastric section from untreated rats shows ulceration of the 
mucosal cells associated with inflammatory changes and necrosis. Animals treated with 
Compound P-28 (100 mg/kg) and pantoprazole(10mg/kg) showed gastric mucosa with intact 
lining epithelium. The mucosal layer and submucosal layer shows mild lymphocytic and 
neutrophilic infiltrates. The muscular and serosal layers appeared within normal limits. 
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                                           RESULTS 
 
DOCKING ANALYSIS 
DOCK SCORE: 
Docking studies of compounds P-01 to P-30 were performed using a nuclear protein Hydrogen 
Potassium ATP-ase receptor (PDB ID: 2ZBD) obtained from the RCSB Protein Data 
Bank,http://www.rcsb.org. Experiments were performed using the program GLIDE (Grid-based 
Ligand  Docking from Energetics) (Maestro version 10.1, Schrodinger , LLC New York) and 
their Dock score are given in the below table:6 
 Table 6:Dock score of designed  compounds 
Compound 
code 
Dock  
score 
Glide 
score 
Lipophilic 
Evd 
W 
phobEn phobEn 
HB 
PhobEn
Pair 
HB 
HBond 
P-01 
 
 
-3.33 
 
-3.33 
-2.42 0 0 0 -0.31 
P-02 -4.05 -4.05 -1.35 0 0 0 -0.26 
P-03 
 
-3.07 -3.07 -1.58 0 0 0 -0.85 
P-04 -6.47 -6.47 -1.21 0 0 0 -1.39 
P-05 
 
-4.63 -4.63 -1.36 0 0 0 -1.33 
P-06 -7.69 -7.69 -2.88 0 0 0 -0.84 
P-07 -6.61 -6.61 -3.08 0 0 0 -0.9 
P-08 -7.59 -7.59 -1.45 0 0 0 -1.52 
P-09 -4.23 -4.23 -1.9 0 0 0 -0.21 
P-10 -4.03 -4.03 -2.01 0 0 0 -0.56 
P-11 -5.16 -5.16 -1.81 0 0 0 -0.46 
P-12 -7.76 -7.76 -2.46 0 0 0 -1.59 
P-13 -5.88 -5.88 -1.36 0 0 0 -0.61 
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P-14 -5.67 -5.67 -2.32 0 0 0 -0.64 
P-15 - 5.89 - 5.89 -1.06 0 0 0 -0.61 
P-16 -6.56 -6.56 -2.37 0 0 0 -0.15 
P-17 -5.54 -5.54 -1.08 0 0 0 -1.94 
P-18 -5.3 -5.3 -2.31 0 0 0 -1.86 
P-19 -6.31 -6.31 -1.52 0 0 0 -1.47 
P-20 -7.66 -7.66 -1.34 0 -1.5 0 -2.56 
P-21 -3.49 -3.49 -1.45 0 0 0 -0.77 
P-22 -4.12 -4.12 -2.7 0 0 0 -0.64 
P-23 -6.54 -6.54 -1.76 0 0 0 -0.45 
P-24 -6.04 -6.04 -1.53 0 0 0 -1.15 
P-25 -6.84 -6.84 -1.11 0 0 0 -0.24 
P-26 -7.77 -7.77 -1.4 0 0 0 -0.35 
P-27 -5.03 -5.03 -2.62 0 0 0 -0.64 
P-28 -8.67 -8.67 -1.41 0 0 0 -0.95 
P-29 -6.57 -6.57 -2.35 0 0 0 -1.37 
P-30 -6.09 -6.09 -2.18 0 0 0 -1.01 
 
Based on the ease of reaction, availability and cost of  chemicals ,synthesis of compounds P-6,P-
12,P-20,P-26  and P-28 were carried out and their physicochemical and spectral characterization 
have been carried out. 
The glide score for the synthesized compounds are given in the below table: 
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                                  Table 7:Glide score of synthesized compounds 
SI 
NO. 
Compound 
code 
                   structures  Chemical name Glide 
score 
 
 
1 
 
 
   P-6 
 
(E)-2-(2-methoxybenzylidene)-
1-(5-chloro-1H-
benzo[d]imidazol-2-
yl)phenyl)hydrazine 
 
 
-7.69 
 
2 
  
 P-12 
 
2-(3-nitrobenzyldene)-1-(4-(5-
chloro-1H-benzo[d]imidazol-2-
yl)phenyl)hydrazine 
 
-7.76 
 
 
3 
 
 
P-26 
 
2-((3H-indol-2-yl)methylene)-1-
(4-(5-chloro-1H-
benzo[d]imidazol-2-
yl)phenyl)hydrazine 
 
 
-7.77 
 
4 
 
P-28 
 
2-((1H-pyrrol-2-yl)methylene)-
1-(4-(5-chloro-1H-
benzo[d]imidazol-2-
yl)phenyl)hydrazine 
 
-8.67 
 
 
 
 
 
DRUG-RECEPTOR INTERACTION 
Interaction of the designed compounds with the receptor H
+
/K
+
ATP-ase was observed 
and studied.Its details were given in below fig: 8,9,10,11 and table:8 
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     P-6 
                       Figure 8: Snapshots of Drug-Receptor interaction 
                    
  
 
  
    Predicted binding mode of   compound P-6 into the catalytic site of 2ZBD 
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P-12 
                     Figure 9:Snapshots of Drug-Receptor interaction         
 
             
 
  Predicted binding mode of compound  P-12 into the catalytic site of 2ZBD 
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P-26 
                  Figure 10:Snapshots of Drug-Receptor interaction 
                   
 
                      
   Predicted binding mode of  compound P-26 into the catalytic site of 2ZBD 
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P-28 
                    Figure 11:Snapshots of Drug-Receptor interaction 
             
 
    Predicted binding mode of  Compound P-28 into the catalytic site of 2ZBD 
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                                        Table 8: Drug-Receptor interaction  
  Sl 
  No. 
 
     Code 
            Compound  
               Name 
 Receptor      Interacting  
       residues 
 
 
1 
 
 
      P-06 
(E)-2-(2-methoxybenzylidene)-1-
(5-chloro-1H-benzo[d]imidazol-2-
yl)phenyl)hydrazine 
 
 
 
 
 
H
+
/K
+
ATP-
ase receptor 
(PDB 
ID:2ZBD) 
a)Pi-Pi stacking with ARG 
489 
 
b)Hydrogen bond(side 
chain)with ARG 489. 
 
 
2 
         
      P-12 
2-(3-nitrobenzydene)-1-(4-(5-
chloro-1H-benzo[d]imidazol-2-
yl)phenyl)hydrazine 
a)Pi-Pi stacking with PHE 487 
 
b)Salt bridge with ARG 489 
and ASP422 
 
 
3 
         
      P-26 
2-((3H-indol-2-yl)methylene)-1-(4-
(5-chloro-1H-benzo[d]imidazol-2-
yl)phenyl)hydrazine 
a)Pi-Pi stacking with ARG560 
 
b)Salt bridge with ARG 489, 
ARG 560 and  MG 997 
 
4 
        
       p-28 
2-((1H-pyrrol-2-yl)methlene)-1-(4-
(5-chloro-1H-benzo[d]imidazol-2-
yl)phenyl)hydrazine 
a)Pi-Pi stacking with ARG 
489 
b)Hydrogen bond (side 
chain)ASP 157 
c)Salt bridge with ARG 489 
and MG 997 
 
SYNTHESIS AND CHARACTERISATION OF DOCKED COMPOUNDS 
SYNTHESIS OF SUITABLE DOCKED COMPOUNDS 
Suitable  benzimidazole derivatives were synthesized and their structures were as represented 
below: 
P-06 
                                 
(E)-2-(2-methoxybenzylidene)-1-(5-chloro-1H-benzo[d]imidazol-2-yl)phenyl)hydrazine 
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P-12 
 
                               
2-(3-nitrobenzydene)-1-(4-(5-chloro-1H-benzo[d]imidazol-2-yl)phenyl)hydrazine 
P-26 
                            
2-((3H-indol-2-yl)methylene)-1-(4-(5-chloro-1H-benzo[d]imidazol-2-yl)phenyl)hydrazine 
P28 
                                                    
2-((1H-pyrrol-2-yl)methlene)-1-(4-(5-chloro-1H-benzo[d]imidazol-2-yl)phenyl)hydrazine 
 
 
CHARACTERISATION OF SYNTHESIZED COMPOUNDS  
a)Melting point 
           Melting points of the synthesized compounds were determined in a one end fused 
capillary tube method by using melting point apparatus and are as provided in the below table:9 
b)Solubility 
              Solubility of the synthesized compounds was checked in various solvents and the 
compounds were found to be soluble in ethanol and DMSO .The results of solubility are as 
provided in the below table:9 
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c)Thin layer chromatography 
                  Thin layer chromatographic analysis was carried out for all synthesized compounds 
by using silica gel G as stationary phase and  Chloroform:Benzene (6:4)as mobile phase. The 
spot was visualized by iodine vapours. Rf value is a characteristic for each of the compound and 
are as provided in the below table:9 
                                  
                                 Table 9: Physical data of synthesized compounds   
 
Sl. 
No. 
 
Code 
 
Molecular  
formula 
 
 
Molecular  
Weight 
(g/mol) 
Melting  
Point 
range 
(
0
c) 
 
Solubility 
 
Rf
* 
 
Percentag
e yield 
1 P-06 C15H13ClN4O 300.74 160-165 Ethanol/ 
DMSO 
0.71 53.1% 
2 P-12 C14H10ClN5O2 315.71 170-172    Ethanol/ 
    DMSO 
0.72 56.89% 
3 P-26 C16H12ClN5 309.75 190-195    Ethanol/ 
    DMSO 
0.77 60.75% 
4 P-28 C12H10ClN5 259.69 140-143    Ethanol/ 
    DMSO 
0.75 64.66% 
         
                                                                                      *Mobile phase-Chloroform:Benzene(6:4) 
                                                                                           Detection – Iodine vapours 
 
SPECTRAL ANALYSIS OF SYNTHESIZED COMPOUNDS 
a)Ultra Violet spectral analysis 
       The maximum absorbance or λmax of synthesized compounds were determined in the region 
of 200-400nm by using Shimadzu UV PharmaSpec 1700 UV-Visible spectrophotometer and the 
results are as provided in the below table: 10 
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b) Infrared spectral analysis 
          The structures of the synthesized compounds were elucidated by JASCO FT-IR 4100 
infrared spectrophotometer in KBr pellets. The results are as provided in the below table:11 
c)Nuclear Magnetic Resonance spectral analysis 
             The structures of the synthesized compounds were elucidated by Bruker AVANCE 500 
MHz NMR Spectrophotometer using DMSO (dimethyl sulphoxide) as internal standard. The 
results are as provided in the below table:12 
d)Mass spectroscopy spectral analysis 
               The structures of the synthesized compounds were to be elucidated by JEOL GC 
MATE II GC-MS. The results are as provided in the below table:13 
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SPECTRAL ANALYSIS 
IR SPECTRA OF P-12                                                         
  
                                                                                                                                                                                                                                                                                                                                                                                                                  
IR SPECTRA OF P-28 
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NMR SPECTRA 
NMR SPECTRA OF P-12 
                                                                             
 
 
NMR SPECTRA OF P-28 
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MASS SPECTRA 
MASS SPECTRA OF P-12 
                                                                       
 
MASS SPECTRA OF P-28 
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       Table 10:UV-Visible spectral data of synthesized compounds 
       Sl.No.    Code             Structures λmax(nm) 
 
        1 
 
 
   P-06 
 
 
 
   309.5 
 
        2 
 
   P-12 
 
 
   312.5 
 
        3 
    
   P-26 
 
 
    358.5 
    
        4 
 
   P-28 
 
 
     325.5 
                   
                      Table 11: Infrared spectral data of synthesized  compounds 
 
                                  
 
                         
         
Sl.No. 
     
Code 
       
                  Structures 
      
              IR(cm
-1
) 
          
1 
P-28 
 
3452:Amine NH stretching 
2853:Aliphatic CH-Stretching 
1629:C=N Stretching 
936:Aromatic CH Bending 
2 P-12 
 
3413: Amine NH stretching 
3234:Aromatic-CH-Stretching 
 2843:Aliphatic CH-Stretching 
 1617:C=N-Stretching 
 1353:Aromatic-NO2-Stretching 
 848   :Aromatic-CH-Bending  
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             Table 12:NMR spectral data of synthesized compounds 
SI 
No. 
Code Structures Functional Groups δvalues 
(in ppm) 
1 P-28 
 
(1H,NH-N=),Singlet 
 
(1H,Ar-H),Multiplet 
 
(1H,CyclicNH),Singlet 
 
(1H,Alicyclic-H,CH),Singlet 
9.63 
 
7.19-8.14 
 
3.6 
 
2.48 
2 P-12  
 
(1H,NH-N=),Singlet 
 
(1H,Ar-H),Multiplet 
 
(1H,Cyclic NH),Singlet 
 
(1H,Alicyclic-H,CH),Singlet 
10.17 
 
7.1-8.4 
 
3.6 
 
2.5 
 
                           
 
 
         Table 13:Mass spectral data of synthesized compounds 
SI.
No. 
Code                  Structures Molecular 
mass(m/z,amu) 
Base 
peak 
Molecular 
ion peak 
1 P-28 
 
          
           335.5 
 
55.7869 
 
     335 
2 P-12 
 
              
            392.5 
 
56.6256 
 
    391.81 
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IN VITRO ANTIOXIDANT ACTIVITY 
DPPH RADICAL SCAVENGING ACTIVITY 
             Table 14:DPPH radical scavenging activity of Ascorbic acid(standard) 
Sl 
No. 
          Sample Concentraction 
(µg/ml) 
% Inhibition 
        ( %) 
        IC50 
       (µM) 
1  
 
    Ascorbic acid 
0.5 2.74  
 
     10.12 
2 1 3.37 
3 1.5 5.08 
4 2 6.66 
5 2.5 7.60 
6 5 20.98 
7 10 50.36 
         Table 15: DPPH  radical scavenging activity of compound P-06 
Sl 
No. 
        Sample Concentraction 
(µg/ml) 
%Inhibition 
        (%) 
      IC50 
    (µM) 
1   
      
            P-06 
50 46.39  
 
    105.7 
2 100 48.22 
3 200 52.91 
4 300 56.57 
5 400 60.06 
6 500 62.98 
  Table 16:DPPH radical scavenging activity of compound P-12 
     Sl 
    No. 
       Sample Concentraction 
(µg/ml) 
% Inhibition 
      (%) 
       IC50 
      (µM) 
1  
 
         P-12 
50 53.34  
 
     47.58 
2 100 61.23 
3 200 62.38 
4 300 68.73 
5 400 76.75 
6 500 88.89 
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  Table 17:DPPH radical scavenging activity of compound P-26 
Sl 
No. 
            Sample Concentraction 
(µg/ml) 
% Inhibition 
       (%) 
    IC50 
    (µM) 
1  
 
           P-26 
50 45.78  
 
     87.06 
2 100 50 
3 200 57.45 
4 300 63.86 
5 400 75.28 
6 500 84.62 
 
                Table 18:DPPH radical scavenging activity of compound P-28 
   Sl 
   No. 
Sample Concentraction 
(µg/ml) 
% Inhibition 
       (%) 
      IC50 
     (µM) 
1  
 
       P-28 
50 60.78  
 
    43.03 
2 100 72.43 
3 200 84.58 
4 300 92.65 
5 400 109.54 
6 500 130.45 
   Graphical representation 
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DPPH radical scavenging activity of compound P-06 and P-12
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ABTS radical scavenging activity 
         Table 19:ABTS radical scavenging activity of Ascorbic acid(standard) 
Sl 
No. 
            Sample Concentraction 
(µg/ml) 
% Inhibition 
       (%) 
     IC50 
    (µM) 
1  
 
         Ascorbic acid 
0.2 26.79  
 
     0.937 
2 0.4 32.17 
3 0.6 34.94 
4 0.8 38.64 
5 1 43.49 
6 1.5 63.04 
7 2 80.22 
 
               Table 20:ABTS radical scavenging activity of Compound P-06 
Sl 
No. 
          Sample Concentraction 
     (µg/ml) 
% Inhibition 
      (%) 
      IC50 
     (µM) 
1  
 
         P-06 
50 42.45  
   83.88 2 100 48.10 
3 150 58.17 
4 200 73.84 
5 250 82.95 
 
                  Table 21:ABTS radical scavenging activity of compound P-12 
Sl 
No. 
           Sample Concentraction 
(µg/ml) 
% Inhibition 
(%) 
     IC50 
     (µM) 
1  
 
P-12 
50 46.78  
 
     58.27 
2 100 64.34 
3 150 73.02 
4 200 82.32 
5 250 88.98 
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          Table 22:ABTS radical scavenging activity of compound P-26 
Sl 
No. 
               Sample Concentraction 
(µg/ml) 
% Inhibition 
        (%) 
       IC50 
     (µM) 
1  
 
P-26 
50 42.54  
 
74.39 
2 100 56.67 
3 150 62.21 
4 200 67.82 
5 250 87.62 
 
                  Table 23:ABTS radical scavenging activity of compound P-28 
Sl 
No. 
          Sample Concentraction 
(µg/ml) 
% Inhibition 
         (%) 
      IC50 
      (µM) 
1  
 
          P-28 
50 57.89  
 
     42.71 
2 100 68.98 
3 150 79.89 
4 200 88.65 
5 250 97.76 
Graphical representation 
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0 100 200 300
0
50
100
150
P-26
P-28
Concentraction(g/ml)
P
e
rc
e
n
ta
g
e
 In
h
ib
it
io
n
(%
)
  
 Figure 17 
 
 
 
 
                                                                                            RESULT 
 
Dept. of Pharmacology .KMCH COP  
 
IN VITRO CELL VIABILITY ASSAY: (Table:24)            
SI 
No. 
Sample Concentraction 
(µM) 
%Viability 
1  
 
P-28 
0.25 97.64 
2 2.5 95.44 
3 25 94.49 
4 50 91.39 
5 100          88.34 
1  
P-12 
0.25 93.33 
2 2.5 89.56 
3 25 85.45 
4 50 83.34 
5 100 79.83 
1  
 
P-26 
0.25 76.34 
2 2.5 74.45 
3 25 68.89 
4 50 64.34 
5 100 55.70 
  
 
                  
                       Figure 18:In vitro cell viability assay of compound P-28 
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Figure19 : IN VITRO CELL VIABILITY ASSAY OF COMPOUND P-28 
Representative photomicrograph shows morphological changes of AGS (Human Epithelial 
Gastric Cells )cells 
                                                                                                                                                                                                 
                             0.25µM                                                                         100µM                                                                                                          
Figure 20:In vitro cell viability assay of compound P-12 
Representative photomicrograph shows morphological changes of AGS (Human Epithelial 
Gastric Cells )cells 
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        Figure 21:In vitro cell viability assay of compound P-26 
Representative photomicrograph shows morphological changes of AGS (Human Epithelial 
Gastric Cells )cells       
                       
      
                     0.25µM                                               100µM 
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ACUTE  ORAL TOXICITY STUDY 
           Table 25: Toxicological sign evaluation of compound P-28 on rats 
 
Sl.No. 
 
Responses 
                        Compound P-28 
         Head        Body        Tail 
Before After Before After Before After 
1 Alertness 
 
Normal Normal Normal Normal Normal Normal 
2 Grooming 
 
Absent Absent Absent Absent Absent Absent 
3 Touch response Absent Absent Absent Absent Absent Absent 
4 Torch response 
 
Normal Normal Normal Normal Normal Normal 
5 Pain response 
 
Normal Normal Normal Normal Normal Normal 
6 Tremor 
 
Absent Absent Absent Absent Absent Absent 
7 Convulsion 
 
Absent Absent Absent Absent Absent Absent 
8 Righting reflux 
 
Normal Normal Normal Normal Normal Normal 
9 Gripping strength 
 
Normal Normal Normal Normal Normal Normal  
10 Pinna reflux 
 
Present Present Present Present Present Present 
11 Corneal reflux 
 
Present Present Present Present Present Present 
12 Writhing 
 
Absent Absent Absent Absent Absent Absent 
13 Pupils 
 
Normal Normal Normal Normal Normal Normal 
14 Urination 
 
Normal Normal Normal Normal Normal Normal 
15 Salivation Normal
  
Normal Normal Normal Normal Normal 
16 Skin colour 
 
Normal Normal Normal Normal Normal Normal 
17 Lacrimation 
 
Normal Normal Normal Normal Normal Normal 
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EVALUATION OF ANTIULCER ACTIVITY 
Table 26:Effect of compound P-28 on Indomethacin induced ulcer 
GROUPS ULCER INDEX(UI) PERCENTAGE (%) 
INHIBITION 
Normal control 
 
00.00 ±00.00 - 
Ulcer control                               
(Indomethacin) 
28.67±0.7601
a
 - 
Low dose(Test 
compound)+Indomethacin 
11.03±0.03
b,c
 61.39±0.90
b,c
 
High dose(Test 
compound)+Indomethacin 
6.85±0.08
b,c
 76.69±0.57
b,c
 
Standard(pantoprazole) 
 
3.83±0.34
b
 86.62±1.16
b
 
All data are expressed as Mean± SEM(n=6).Statistical comparison: One way analysis of 
variance (ANNOVA) followed by Tukey test. 
a
***P<0.001,ulcer control was compared with 
normal control, 
b***
P<0.001 standard (10mg/kg) and drug treated groups were compared with 
ulcer control, 
c***
P<0.001,drug treated groups compared with standard. 
Graphical representation: 
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                                                        Figure 23 
INDOMETHACIN INDUCED ULCER: 
 
             
                            Normal                                                      Ulcer control 
                                             
                  Low dose                                  High dose                                    Standard 
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Table 27: Effect of compound P-28 on pylorus ligation induced ulcer 
           Group ULCER INDEX(UI) PERCENTAGE                         
INHIBITION(%) 
         Normal control               00.00±00.00 - 
          Ulcer control   19.00±0.73
a
 - 
   Low dose+ pylorus ligation 6.76±0.05
b,c
 65.11±1.25
b,c
 
  High dose+pylorus ligation 5.06±0.03
b,d
 73.41±1.38
b,c
 
   Standard(pantoprazole) 3.33±0.02
b
 82.55±0.91
b
 
All data are expressed as Mean± SEM(n=6).Statistical comparison: One way  analysis of 
variance(ANNOVA ) followed by Tukey test. 
a
***P<0.001, ulcer control was compared with 
normal control , 
b
***P<0.001 standard (10mg/kg) and drug treated groups were compared with 
ulcer control, 
c***
P<0.001,
d***
P<.01 ,drug treated groups compared with standard.
Graphical representation: 
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                                                               Figure 25 
PYLORUS LIGATION INDUCED ULCER: 
              
                       Normal                                                                  Ulcer control 
        
                    Low dose                             High dose                               Standard 
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Table 28: Effect of compound  P-28   on  Gastric secretion, Total and Free acidity  pH  of  
gastric juice using pylorus ligation induced ulcer 
Group Gastric volume 
(ml/100g) 
pH of gastric 
juice 
Total acidity Free acidity 
 Normal control 1.28±0.03  2.67±0.006 54.21±0.68 29.82±0.54 
Ulcer control 2.58±0.009
a
 1.43±0.10
a
 87.37±0.72
a
 57.32±0.53
a
 
 Low dose 1.83±0.004
b,d
 1.85±0.006
b,d
 67.40±0.51
b,d
 38.81±1.03
b,d
 
High dose 1.63±0.01
b,d
 2.49±0.007
b,c
 60.44±0.88
b,d
 33.89±0.76
b,e
 
Standard 1.30±0.006
b
 2.55±0.006
b
 56.58±0.50
b
 30.32±1.15
b
 
All data are expressed as Mean± SEM(n=6).Statistical comparison: One way analysis of 
variance(ANNOVA) followed by Tukey test. 
a
***P<0.001,ulcer control was compared with 
normal control, 
b***
P<0.001, standard (10mg/kg) and drug treated groups were compared with 
ulcer control, 
c*
P<0.05,
d***
P<0.001,
e**
p<0.01 , ns: non significant, drug treated groups compared 
with standard 
Graphical representation: 
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                     Figure 26:Effect of compound P-28 on gastric volume 
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                                     Figure 27: Effect of compound P-28 on pH  of gastric juice 
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                                       Figure 28: Effect  of compound P-28 on total acidity 
Free acidity 
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                                                     Figure 29:Effect of compound P-28  on free acidity 
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GRAPHICAL REPRESENTATION: 
EFFECT OF COMPOUND P-28 ON TOTAL PROTEIN AND ANTIOXIDANT LEVELS 
IN INDOMETHACIN INDUCED ULCER MODEL
Figure 30: ESTIMATION OF TOTAL 
PROTEIN: 
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   Figure 31: ESTIMATION OF SOD: 
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Figure 32: ESTIMATION OF CATALASE: 
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             Figure 33: ESTIMATION OF GPX:  
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Figure 34: ESTIMATION OF GSH: 
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      Figure 36: ESTIMATION OF LPO: 
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Figure 35: ESTIMATION OF MPO: 
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EFFECT OF COMPOUND P-28 OF TOTAL PROTEIN AND ANTIOXIDANT LEVELS 
IN PYLORUS  LIGATION  INDUCED ULCER MODEL:
Figure 37: ESTIMATION OF TOTAL 
PROTEIN:                                                                     
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               Figure 38: ESTIMATION OF SOD: 
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Figure 39: ESTIMATION OF CATALASE: 
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Figure 40: ESTIMATION OF GPX:                                                                                                                                            
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Figure 41: ESTIMATION OF LPO: 
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     Figure 43: ESTIMATION OF GSH: 
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Figure 42: ESTIMATION OF MPO: 
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HISTOPATHOLOGICAL STUDIES: 
INDOMETHACIN INDUCED ULCER: 
                                           Figure 44: GROUP I:(NORMAL) 
                                       
 Section from stomach shows normal epithelium. Submucosa shows no significant pathology. 
There is no malignancy/granuloma seen. 
                
Figure 45:GROUP II:(ULCER CONTROL:INDOMETHACIN ONLY) 
                                       
 Laminapropria shows few scattered chronic inflammatory infiltrates. Submucosa shows 
significant pathological changes. Gastric section form untreated rats shows ulceration of the 
mucosal cells associated with inflammatory changes and necrosis. 
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         Figure 46: GROUP III:(STANDARD:PANTOPRAZOLE) 
                             
Section from stomach shows normal epithelium. Laminapropria shows mild inflammatory 
infiltrates. Blood vessel shows congestion. There is no malignancy/granuloma seen. 
 
 
                     Figure 47: GROUP IV: (LOW DOSE, 50mg/kg) 
                               
Section from stomach shows normal epithelium. Laminapropria shows mild   lymphocytic infiltrates. 
Submucosa shows mild lymphocytic and neutrophilic infiltrates. Muscular layer shows no significant 
pathology. 
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                         Figure 48: GROUP V: (HIGH DOSE,100mg/kg) 
                                 
Section from stomach shows normal epithelium. Laminapropria and sub mucosa shows mild  
lymphoplasmacytic infiltrates. There is no malignancy/granuloma seen. 
 
PYLORUS LIGATION INDUCED ULCER: 
                            Figure 49: GROUP I :(ULCER CONTROL) 
                                    
Few glands show reactive atypia. Laminapropria shows scattered chronic inflammatory 
infiltrates and neutrophils. Submucosa shows congested vessels and chronic inflammation. 
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             Figure 50: GROUP II: (STANDARD:PANTOPRAZOLE) 
                                
Section from stomach shows normal epithelium. Laminapropria shows mild inflammatory 
infiltrates. Submucosa  shows  inflammation. There is no malignancy/granuloma seen. 
 
 
                       Figure 51: GROUP III: (LOW DOSE,50mg/kg) 
                                      
Section from stomach shows normal epithelium. Laminapropria shows mild lymphocytic 
infiltrates. Submucosa shows mild lymphocytic and neutrophilic infiltrates. Muscular layer 
shows no significant pathology. 
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                              Figure 52: GROUP IV: (HIGH DOSE,100mg/kg) 
                                    
 Section from stomach shows normal epithelium. Laminapropria shows mild lymphocytic 
infiltrates. Submucosa shows no significant pathology. There is no malignancy/granuloma seen 
                                                                                      CONCLUSIONS 
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                                         CONCLUSIONS 
 
 A total of 30 compounds were designed for studying on its binding affinity with the 
H
+
/K
+
-ATP ase receptor. 
 The docking analysis of the designed compounds with H+/K+-ATPase receptor was 
studied using the Glide software version 10.1, Schrodinger, LLC, New York, NY, 2015. 
 Based on dock score and interaction, 4 of the best compounds were selected and 
synthesized. 
 The structures of the synthesized compounds were characterized by UV, IR, NMR and 
Mass spectral data. The data’s of the analytical spectra’s were correlating with the 
structures of the synthesized compounds. 
 The melting point and Rf of the synthesized compounds were checked to determine the 
physical properties and purity of compounds. 
 In vitro antioxidant studies such as DPPH and ABTS radical scavenging activity of the 
synthesized compounds was carried out. It was revealed that the compounds have a 
slightly lower free radical scavenging activity than that of standard (ascorbic acid). 
 In vitro cell viability assay was carried out using AGS (human epithelial gastric cells) 
inorder to confirm the capability of synthesized compounds to sensitize the target cell 
mainly the gastric cell. 
 The antiulcer activity of the compound P-28 was carried out using two models 
Indomethacin induced and Pylorus ligation induced ulcer .Based on the results, 
compound P-28  exhibited as antiulcer activity as that of standard pantoprazole. These  
action may be possibly due to the inhibition of H
+
/K
+
-ATP ase enzyme responsible for 
the gastric acid secretion. 
 So further studies can be carried out to test the potency of the compound and can be used 
as a lead for the development of newer antiulcer agents. 
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